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After one year with access to the SAF-304-G04-H grant, a performance based funding from 
the Global Fund to fight AIDS, Tuberculosis and Malaria, the Western Cape Province has 
been able to race ahead with the antiretroviral rollout. The Global Fund's contribution has 
helped enable the province to provide antiretroviral treatment to 65% of the people who 
desperately need it, which is a stark contrast to the South African national average receiving 
treatment of 10%. 
This dissertation illustrates how the Global Fund grant has clearly met and in some cases 
exceeded its targets particularly in relation to antiretroviral (ARV) treatment in its first year. 
Based on the research carried out as part of the preparation of this dissertation, it became 
clear that the Western Cape's progressive and committed management team was 
instrumental in successfully providing increased access to ARV treatment compared to other 
provinces. Other factors that have contributed to the success of the grant project include the 
fact that in 1999 the province first initiated the provision of antiretroviral drugs to help 
prevent HIV positive women transmitting the infection to their infants. With the experiences 
gained from both the introduction of treatment drugs and from the valuable experience 
gained from the pilot ARV rollout projects in Khayelitsha and Gugulethu, the battle against 
HIV and AIDS has grown stronger. 
The findings of this dissertations support the impression that the arrival of the funds from 
the Global Fund grant and other national funds, has created a basis for a successful 
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More than 40 million people worldwide are HIV positive. Since AIDS was first discovered 
more than 25 million people have died as a result of the disease. Antiretroviral treatment is 
widely available in developed countries, while access to antiretrovirals (ARVs) in poorer 
countries has been inadequate. The World Health Organisation estimated in June 2005 that only 
I million people out of the 6 million people needing the life saving ARV medication were 
receiving it (WHO, 2005). 
Access to antiretroviral treatment has caused much controversy in South Africa. With more 
than 5.2 million South Africans affected with HIV/AIDS, South Africa is the country with the 
highest number of people infected, and AIDS is the country's number one killer (Dorrington et 
ai, 2001). The arrival of antiretroviral treatment (ART) has given hope to millions of people 
living with HIV I AIDS; however access and commitment, from the South African government, 
to provide the life saving drugs has been limited. 
The Provincial Department of Health in the Western Cape was the first to start providing ART 
in South Africa. As funds for ART in South Africa were limited, the department applied for 
external funding from the Global Fund to fight AIDS, Tuberculosis and Malaria in 2003. The 
proposal was successful, allowing the Western Cape to rapidly increase their efforts on AIDS 
treatment though out the province by employing more people on the ART campaign. This has 
resulted in the Western Cape rollout being hailed as the ARV success story of the country, with 
more than 11 000 people living with HIV I AIDS receiving ART, a quarter of whom are funded 
by the Global Fund (Cloete, 2005, personal comm., 30 Aug). It was further estimated that at the 
end of2005 65% of those in need of ARV treatment in Western Cape would have had access to 
the lifesaving drugs, a figure considerably higher than the South African national average of 
10% (Herman, 2006). 
This dissertation will explore and demonstrate that the Global Fund grant in the Western Cape 
is a successful project grant. It will show how it in its first year the project grant has met the 
targets and objectives set by the Global Fund, especially those concerned with antiretroviral 
treatment. Furthermore this dissertation seeks to identify the key factors, which can be 
attributed to the success of the Global Fund grant given to the Western Cape Provincial Health 











The first chapter provides an introduction to HIV / AIDS. This enables the reader to understand 
terms and issues around HIV and AIDS. It covers areas such as the discovery of AIDS, how 
HIV prevalence estimates are made and what antiretrovirals are. The latter half of the chapter 
focuses on access to ARVs in South Africa in light of AIDS policies. This chapter provides the 
reader with a better understanding of the political issues that will be referenced through out the 
entire dissertation. 
The second chapter describes the research methodology. It provides details of how the primary 
research for this dissertation was conducted, who was interviewed during the course of the 
research, and why those individuals were of particular interest. 
The third chapter concentrates around HIV / AIDS in the Western Cape. It gives the reader an 
insight into the historic background of ARV treatment and highlights how committed the 
Western Cape were to HIV/AIDS at a much earlier stage than other provinces. 
Thefourth chapter provides the reader with information about the Global Fund and its quest to 
fight AIDS, Tuberculosis and Malaria. It seeks to provide a comprehensive overview of the 
institution and how it operates. It provides an understanding of why the performance review 
process is such an essential part of the Global Fund. 
The fifth chapter provides a detail description of the grant (SAF-304-G04-H) given to the 
Western Cape. Here it is argued that the grant is a successful grant, mainly due to it having met 
the targets set by the Global Fund. The last part of this chapter discusses the general rollout of 
antiretrovirals, in the Western Cape and its relation to the Global fund. 
The sixth chapter presents the main finding of this research. It argues that factors such as 
partnerships, previous experience, good management, timing and synergy played an important 
role in the success of the grant. 











CHAPTER 1: HIV/AIDS and the South African epidemic 
UNAIDS estimated that some 40 million people worldwide were living with HIV/AIDS in 
2005. HIV/AIDS has been described as the most devastating plague in modern times, killing 
over 25 million people thus far (UNAIDS, 2005). HIV has been around for 25 years (Abdool 
Karim, 2005, p.32), and it is spreading at an alarming high rate with an estimated 14 000 people 
becoming infected each day (UNAIDS, 2005). This chapter of the dissertation will explore the 
following questions: What is HIV/AIDS, how does it spread, and how can it be treated? This 
will provide the reader with a good basic understanding of the epidemic before delving into 
further issues surrounding HIV / AIDS. 
AIDS was first discovered in June 1981 in homosexual men in Los Angeles. At first 
researchers assumed the disease only affected homosexuals; however in December 1981 it 
became known that the disease also affected injecting drug users (lDUs) and other groups, the 
perception then changed. By 1982 the disease was named Acquired Immuno Deficiency 
Syndrome (AIDS), however the discovery and isolation of the Human Immunodeficiency Virus 
(HIV) was not until 1983 (Abdool Karim, 2005, p.32). 
HIV is a retrovirus which attacks CD4 + T- cells where it integrates itself into human DNA, 
and gradually destroys the immune system (Morris and Cilliers, 2005, p.79). HIV enters the 
body through unprotected sexual intercourse, intravenous drug use with needles, transmission 
from mother to child in pregnant women, use of infected blood for blood transfers, or through 
direct contact with open wounds. Within the first weeks of infection there is a high level of 
virus replication, but after a few weeks the immune system responds to HIV and the viral load 
declines (Morris and Cilliers, 2005, p.85). HIV positive people thus look healthy and normal 
for the first years of infection. It is only when the virus has managed to destroy the immune 
system (by reducing the number of CD4 cells) and increasing amount of opportunistic 
infections like Tuberculosis, occur as a result of the weakened immune system, that the patient 
develops AIDS. The time between HIV infection and the development of AIDS takes on 
average 8-10 years (ibid). 
HIV/AIDS is an international epidemic with cases on every continent (UNAIDS, 2005). It is 











everywhere, however fastest in Eastern Europe and Russia, with only a few countries like 
Brazil and Uganda having experienced a decline in infections (UNAIDS, 2005). As illustrated 
below UNAIDS estimates that in 2005 over 40 million people were living with HIV/AIDS. A 
total of 4.9 million people became infected with HIV in 2005, while a further 3.1 million were 
estimated to have died of AIDS in 2005 (UNAIDS, 2005). At the present time there are no 
cures or reliable vaccines for AIDS and without antiretroviral drugs the patient will die shortly 
after having developed AIDS. 
The table below from UNAIDS gives a regional summary of HIV/AIDS in 2003 and in 2005. 
From the table one can see that Sub-Saharan Africa is by far the region hardest hit by 
HIV/AIDS. Over 25 million people are infected with HIV/AIDS in this region, making Sub-











Regional HIV and AIDS statistics and features, 
I 
2003 and 2005 
I 
Adults and children Adults and children Adult prevalence Adult and child deaths I 
living with HIV newly infected with HIV (%)' due to AIDS i 
Sub·Saharan Africa 
I 2005 25.8 million 3.2miUion 7.2 2.4 miUion 
123.8-28.9 mJtiionl 12.8-3.9 million] 166-80) 12.1-2.7 mation] 
I 
2003 24.9 million 3.0 miHion 7.3 2.1 miUion 
123.0-27. 9 mitiionj [2.7-3.7 million] 167-81] 11.9-2.4 mHlionj 
North Africa and Middle East 
2005 5,0 000 6t ODD 0.2 5B 000 
1230000-1.4 millionl 135000-200 000] [0.1-0.71 125000-145 ((10) 
2003 50D 000 62000 0.2 55000 
[200000-1.4 million] 131 000-2OCl 0001 /D.l-0.l) 1220((1-140000] I 
South and South·East Asia , , 
2005 7.4 million 900 ODD 0.7 400 000 I 
14.5-1Hl million] 1480000-2.4 milli:Jnl 10.4-1 OJ 1290000-740(00) 
2003 6.5 million B40 ODD 0.6 390000 
14.0-9.1 million] [410000-2.0 million) 10.4-O.9J 1240000-590 OOOl 
East Asia I 
2005 870000 140000 0.1 41000 
[440000-1-4 million) [42 000-3S() 000; [005-0.21 120 OOll-BB O~()l 
2003 690000 lOC1OOO O. T 22000 
1350000-1.1 millbn) [33 000-3((1 000) 1004-0.1] 111 000-310001 
Oceania 
2005 74000 8200 0.5 3600 I 
[45000-120 ODD) [2400-25000J [O.2-O·11 11700-8200] I 
I 
2003 63000 8900 0.4 2000 I 
138 000-99 000) [2600-27 0(0) [0.2-0.6) [91O-4oo0l I 
Latin America 
2005 1.8 million 200000 0.6 66000 
(1.4-204 millbnJ [130 000-360 OlXll [O.~.81 [52000-86 000] 
2003 1.6 mJllion 170000 0.6 59000 
[1.2-2.1 millionj [120000-3100lXl] 10.4-0.81 [46000-77 0001 
Caribbean 
2005 300000 30000 1.6 240((1 
1200 000-510 0001 [17 000-710001 [l.1-2·11 [16 000-40 O:xl] 
2003 30G 000 29000 1.6 2400Cl 
[200 000-510 0001 [17000-68 DOO) [1.1-2.7) 116000-40000] 
Eastern Europe and Central Asia . 
2005 1.6 million 270008 0.9 62000 
[900 000-2.3 million] [140000-610 Ol()] 10.6-1.3) [39000-91 O::xJJ 
2003 1.2 million 210 000 0.7 36 DOD 
1140 OCIO-l.8 million) (120000-6800lXl) 10.4-lll] 124 D00-52 O::xJl 
Western and Central Europe 
2005 l20000 :.12 O~O 0.3 12000 
1570000-890 ODD] [15 000-39 000) 10.2-0.4) <150lXl 
2003 (OJ 000 20000 0.3 12000 
1550 000-870000) 113000-37 OOOJ 10.2-0.4) <15000 
North America 
2005 1.:.1 million 43000 0.7 18000 
1650 OlXl-l.B mittion] 115000-120 000) 10A-UJ 19 0::xJ-30 000] 
2003 1.1 mHlion 43000 0.7 18000 
i 1570 mO-1.$ million) [15000-120 0001 IO.3-1.1J 19 000-30 O((l! 
TOTAL 
2005 40.3 million 4.9 miNion 1.1 3.1 miDion 
136.7-45.3 millior [4.3-6.6 million] 11.0-Ul [2.8-3.6 mulion] 
2003 3;t.Smillion 4.6 miHlon 1.1 2.8 minion 
134.0-41. 9 millior 140-6.0 million1 11.0-1.2) 12.5-3.1 mil ion' 











The 2005 UNAIDS epidemic update estimates that 29.5% of South Africans (aged 15-49) are 
living with HIV I AIDS, which makes South Africa the country with the highest total number of 
HIV positive people in the world. 
The scale of the HIV/AIDS epidemic 
To understand the enormity of HIV/AIDS it is important to understand how estimates of HIV 
infection levels are made. HIV/AIDS statistics are usually extrapolated from annual antenatal 
surveys, which are generated into estimates (Gouws and Abdool Karim, 2005, p.52). Firstly the 
local/regional antenatal prevalence rates are collected by counting the number of HIV positive 
pregnant women accessing antenatal care where they are tested for HIV in the various public 
clinics (Department of Health, 2005). The local/regional surveys are then used to determine the 
national HIV antenatal prevalence statistics. This data is extrapolated to the sexually active 
population, often described as the age group between 15 and 49 (UNAIDS, 2005). It is this 
estimation process which proves the basis for most national estimates of HIV prevalence and 
incidence. 
The antenatal prevalence in South Africa has risen dramatically over the last 15 years. From a 
low 0.8% in 1990 to 29.5% in 2005, with some areas showing more than lout of 3 pregnant 
women testing positive for HIV (Department of Health, 2005). 
I· Prevalence of HIV among antenatal care attendees in South 
Africa, 1990- 2004 
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Figure 2 : ESTIMATED PREVALEl"CE OF HIV AMONG ANTENATAL CARE ATTENDEES IN SOliTH AFRICA, 1990- 2004 











Access to ARVs 
For those who are living with HIV/AIDS today, medical science has turned 'AIDS - the death 
sentence' into 'AIDS - the chronic disease'. In Western Europe and in the United States the 
number of people dying of AIDS has been reduced, despite increases in new HIV infections 
(UNAIDS, 2005). By taking Highly Active Antiretroviral Treatment (HAART) I correctly for 
the rest of life, HIV/AIDS becomes a 'chronic disease' and not an immediate death sentence. 
Access to antiretroviral treatment (ART) has, despite being reported to work as early as in 1996 
at the International AIDS Conference in Vancouver, been limited in most parts of the world 
(WHO, 2005). 
Highly Active Antiretroviral Treatment is usually a combination of three ARV drugs which 
together suppress the HI virus, allowing a rise in CD4 cells (Wood, 2005, p.506). ARVs delay 
the progression of HIV, strengthening the immune response and allowing the immune system 
to recover from and fight off infection (ibid). Since a high count of CD4 cells is essential for a 
strong immune system, the average CD4 count for a healthy individual is around 1000, a rise in 
CD4 cells from 200 to 800 has a dramatic effect on a patients well being (WHO, 2005). ARVs 
manage to kick patients back into good health, because it helps HIV positive people to fight off 
opportunistic infections. HIV at its worst can eliminate all CD4 cells in a body (eliminate the 
immune system), which allows the patient to die of any infection, even from the flu. However 
ARVs not only prevent people from dying from AIDS, they improve quality of life, and allow 
people living with HIV/AIDS to live normal, healthy lives (Wood, 2005, p.505-506). When 
taken correctly, triple therapy can often lead to undetectable HIV viral levels (ibid), making 
transmission of HIV less frequent (Nattrass, 2004, p.II8). ARV treatment is thus not only 
beneficial for the individual receiving the drugs, it is also beneficial in terms of HIV 
prevention .. 
Through global initiatives like the Global Fund to fight AIDS, Tuberculosis and Malaria and 
the US President's Emergency Plan For AIDS Relief (PEPF AR) access to antiretroviral 
treatment has been made increasingly possible. Despite this, most people in need of ARV 
treatment still do not have access to the life saving drugs. With initiatives like the World Health 
Organization's (WHO) '3 by 5' (treat 3 million HIV positive by 2005) only reaching around 1 
1 HAART is made up by a combination of anti ret rovira Is (ARVs), which suppress the viral load, making 
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remained. It is suggested by van der Vliet (2004, p.S3) that this factor may have contributed to 
the AIDS Plan diminishing in priority and becoming just another one of the many challenges 
facing the new government. 
Nelson Mandela had originally intended to make HIV/AIDS one of his government's priorities, 
and later expressed regret that more emphasis had not been placed on stopping the epidemic 
when there was still hope of avoiding a public health disaster (Heywood, 200S, p.3 76). 
With AIDS not being at the forefront of the government's policies, a somewhat sad attempt was 
made to stop the epidemic (Sarafina and Virodene), which resulted in controversy, denial and 
mistrust which is still present in South Africa today. 
Sarafina and Virodene 
In 1995 the first of the attempts to educate the people about HIV and AIDS was made by the 
Department of Health commissioning a musical, Sarafina II, with the intention of making 
HIV/AIDS prevention through a cultural play (van der Vliet, 2004, p.SS). The idea was to 
produce a sequel to the widely popular film 'Sarafina'. It was an expensive production, 
absorbing R14.2 million of the AIDS budget. AIDS activists and experts were not consulted, 
and felt excluded from the process (ibid). In addition, the money was from the European Union 
and the government had failed to ask for permission to spend the funds specifically on a 
musical. All this resulted in public protest and disagreements, which led to an investigation by 
the Public Protector, and a successive cancellation of the project (Nattrass, 2004, p.4S). 
Sarafina II marked the start of mistrust between AIDS activists, AIDS experts and the national 
Department of Health. 
Still, whilst the Sarafina investigation was carried out, in 1997 the South African government 
managed to cause another stir around AIDS with a proposal of introducing Virodene POS8, an 
AIDS 'cure' drug (Deane, 200S, p.S39). At this time it was well documented that ARVs were 
effective, however the government proceed to claim that this drug would cure AIDS. The drug 
was developed by three scientists in Pretoria, and was backed by senior officials and 
government ministers to be a miracle cure for AIDS. Patient testimonies were put forward 











tests, and it was rejected several times by the South African Medicines Control Council (MCC) 
(ibid). None of the researchers that put Virodene forward were experts on HIV and AIDS (ibid, 
p. S40). 
Furthermore activists, experts and the international medical community started questioning the 
effects of Virodene, which led to a joint enquiry by the Gauteng Provincial Department of 
Health and the University of Pretoria of the drug. The result of which was the finding that 
Virodene contained the extremely toxic industrial solvent dimethyl formam ide, which could 
cause cancer and liver damage. In addition patients that had taken the drug had reported 
irritations (Deane, 200S, p.S39). Therefore the MCC refused to allow the use of Virodene 
whilst AIDS patients continued to beg for access to the drug (Nattrass, 2004, p.46). An 
additional outcome of the investigation were allegations around the government's financial 
involvement in Virodene (Deane, 200S, p.S40; Nattrass, 2004, p.46). 
It was widely recognised that ARV treatment is an effective medication for people infected 
with HI V, however the South African government managed to cause confusion around 
established medical facts, marking the Virodene scandal as the start of the government 
questioning the reliability of science. This became prominent when Thabo Mbeki became the 
South African President in June 1999 (Nattrass, 2004, p.46). Following President Mbeki's 
choice to instead of engaging in constructive debates rather accused those who opposed him of 
'plotting against him', which ultimately lead to the replacement of the then leader of the MCC 
and other key personnel (Nattrass, 2004, p.46). People, who had hoped for access to 
antiretroviral treatment through the public health system, were naturally disappointed by the 
government's policies. 
AZT 
In October 1998 Health Minister Dr. Nkosazana Dlamini-Zuma announced that she and nine 
provincial health ministers had decided to focus on HIV prevention and not make AZT 
(zidovudine) available to pregnant women (van der Vliet, 2004, p.S6). This was a blow for 
activists who wanted to use antiretrovirals to prevent HIV infection in infants. In 1998 it was 
well known that AZT treatment could reduce the chance of HIV transmission from mother to 











Nkosazana Dlamini-Zuma claimed the drug was too expensive and that the government could 
not be responsible for the prevention of mother-to-child-transmission (PMTCT). She said that 
the cost of testing all pregnant women, providing counselling and providing formula feeding 
was far too high for the government to cope with. Dr. Nkosazana Dlamini-Zuma still persisted 
in making these claims even while scientists and economists showed that PMTCT was 
affordable (Nattrass, 2004, chapter 3). Allegations around AZT being toxic started to surface 
and naturally created a storm of protests against the government. In the middle of these issues, 
on 10 December 1998, the activist organisation, Treatment Action Campaign (T AC), was born 
(Robins, 2004, p.662).2 The international face ofTAC, Zackie Achmat (a former anti-apartheid 
gay activist and openly HIV positive), together with the rest of the T AC leaders, later turned 
out to be the major activist organisation in South Africa, particularly at the forefront for 
demanding treatment. 
The first provincial rebellion against national AIDS policies came in 1999 when the Western 
Cape, at the time not under ANC control, decided to pilot AZT and formula feeding at two sites 
in Cape Town in order to reduce mother to child transmission of HIV (Abdullah, 2005, 
personal comm., 23 Sept). This was not popular with the national government, who accused the 
Western Cape of playing games with peoples lives by using the rumoured toxic drug AZT 
(Goemaere, 2005, personal comm., 5 Aug). 
After the 1999 elections, Dr. Nkosazana Dlamini-Zuma became the foreign minister, whilst Dr. 
Manto Tshabalala-Msimang became the new health minister. Hopes that the new health 
minister would be strongly committed to fighting AIDS were soon crushed. The Mbeki 
government and Dr. Manto Tshabalala-Msimang caused even greater controversy than the 
previous administration. The outrage started in October 1999 with President Mbeki addressing 
the National Council of Provinces, claiming AZT to be toxic (van der Vliet, 2004, p.58). Dr. 
Manto Tshabalala-Msimang shortly thereafter put forward that AZT weakened the immune 
system and could lead to mutations in babies (ibid). The fact AZT was on the list of the World 
Health Organisation's essential drugs, and that the US Centres of Disease Control and the 
South African MCC had approved it, appeared not to affect the president or the health minister. 
Then in January 2000, the government appointed the South African National AIDS Council 











(SANAC), causmg further criticism. The council comprised of 15 cabinet ministers, one 
representative from an AIDS organisation, three representing sport, hospitality and 'celebrities', 
and two traditional healers (van de Vliet, 2004, p.58). There were no scientists, no medical 
practitioners; nobody representing the big AIDS organisations, such as T AC, and no 
representatives from MCC or the Medical Research Council. This left the activists extremely 
disappointed as they had hoped for a multi-sectoral and inclusive council. 
AIDS dissidents 
In early 2000 the situation got worse for AIDS activists, when President Mbeki set up the 
'Presidential International Panel of Scientists on HIV I AIDS in Africa'. Dissidents of the 
conventional scientific view that AIDS is caused by HIV, such as David Rasnick and Peter 
Duesberg, were invited onto this panel (van der Vliet, 2004, p.59). The dissidents questioned 
the very existence of AIDS and believed that AIDS was caused by poverty and not by HIV. 
Such views appeared to have the support of President Thabo Mbeki (Nattrass, 2004, p.49; van 
der Vliet, 2004, p.59). This created confusion around the understanding and importance of 
antiretroviral treatment, with the dissidents going as far as claiming that antiretroviral drugs 
actually gave people AIDS. Many published articles such the illustration below highlighted the 
growing frustration of the public and activists. 
In addition in April 2000, President Mbeki took the unprecedented step of writing to world 
leaders, such as the UN Secretary General Kofi Annan, British Prime Minister Tony Blair and 
US President Bill Clinton, requesting them to revisit the issue of AIDS (van der Vliet, 2004, 
p.59). This letter caused massive criticism, as it was rumoured to disclose to the major world 
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Figure 5: COMIC ILLCSTRATlO:-O OF THE PRESIDENTIAL INTERNATIONAL PANEL OF SCIENTISTS ON HIV/AIDS IN AFRICA' 
(MAIL & GlTARDIA:-O 161\1ARCH 2000) 
South Africa was chosen to host the July 2000 International AIDS conference in Durban. The 
conference coincided with the height of the debate surrounding the dissident views. This 
worried the conference chairperson, Professor Coovadia, who pleaded with President Mbeki to 
steer clear from scientific debates (van der Vliet, 2004, p.59). Preceding the conference the 
journal Nature published the article' Durban declaration' where 5000 scientists proclaimed the 
aim of the conference was to clarify the scientific explanation of HIV and AIDS (van der Vliet, 
2004:, p.60). Disappointingly, President Mbeki opened the AIDS conference by claiming that 
poverty was the number one killer, and that AIDS was a disease of poverty, hence fighting 
poverty was more important. This caused much anger and eventually President Mbeki officially 
withdrew from the AIDS debate in October 2000 (van der Vliet, 2004, p.61). In a little more 
than a year, the President had managed to split the government and the activists and South 
Africa was not united in the fight against AIDS. 
Pharmaceuticals and Nevirapine 











Pharmaceutical Manufactures' Association (PMA), after the South African parliament passed 
the Medicines and Related Substance Control Amendment Act (Nattrass, 2004, p.52). The act 
gave the government the ability to import generics produced before a patent had expired, 
something the PMA claimed violated the World Trade Organisation rules. The South African 
government refused to back down, and the standstill eventually ended up in court in March 
200 I (ibid). T AC fought alongside the government, ultimately leading to the PMA backing 
down and offering to settle the case. Despite this victory, TAC and the government were still 
very much at opposite ends in the fight against AIDS. This clearly came to show in the PMTCT 
court case. 
In early 200 I the South African government announced that selected hospitals would offer HIV 
tests to pregnant women (van der Vliet, 2004, p.75). Those who tested positive would receive 
Nevirapine and baby formula. The decision had not gone through parliament and was referred 
back to cabinet. By July 200 I nothing had been actioned so T AC instigated legal measures to 
force the government to provide Nevirapine (ibid). The government officials argued that 
PMTCT was still too expensive and unaffordable. However in 200 I the court decided in favour 
of TAC and denied an appeal in 2002 (ibid). Thus forcing the government to provide 
Nevirapine to HIV positive pregnant women. 
ARV rollout in South Africa 
After the success with the fight for Nevirapine, T AC and other activist groups demanded free 
access to antiretroviral treatment. Even though prices had decreased dramatically, the 
government was still unwilling to commit to free access to ARVs based on the argument of 
expense, despite reports by academic researchers arguing that ARV treatment was actually 
affordable for the South African government (see Geffen, Nattrass & Raubenheimer, 2003; 
Nattrass, 2004). Furthermore despite international reactions and pressure the South African 
government kept their stand for over a year. 
On 8 August 2003, the South African Cabinet requested the Department of Health to prepare a 
plan for ARV treatment (Sidley, 2003). It would become the last part of the 'National Strategic 
Plan for HIV and AIDS 2000-2005', which in addition addresses prevention, care and support. 











been waiting for this day for several years. It took months before the national rollout began to 
take place and progress has been slow in many provinces. 
The ARV rollout in South Africa started in 2004 with each province having been allocated 
funds and developed their own systems for delivery within the national treatment guidelines 
(Cloete, 2005, personal comm., 30 Aug). If patients had a CD4 count of less than 200 or 
showed signs of being in the final stage of the disease, they qualified for ARV treatment. 
However, to start treatment the patient must be free of Tuberculosis (Department of Health, 
2004c, p.4). The guidelines demands that patients must first receive TB medication before 
initiating ARVs. In addition patients must demonstrate reliability through attendance at three 
or more scheduled clinical visits; they must not be actively abusing alcohol or other substances; 
they must not have untreated active depression; patients must have disclosed their HIV status to 
at least one friend or family member or have joined a support group; and the patient must be 
able to attend regular visits at the ARV site (Department of Health, 2004c, p.3). The strict 
criteria for ARV treatment helped ensure that patients were ready and committed to the 
treatment, because ARV treatment must be taken every day for the rest of a patient's life, so 
adherence to the drugs is vital. 
The ARV rollout has progressed in all the South African provinces, however at different paces. 
Some provinces like the Western Cape and Gauteng have been able to rollout ARV treatment 
quite successfully, while other provinces like the Eastern Cape have not managed to put enough 
people on ARV treatment (Maartens, 2005, personal comm., 4 Aug). The programme has 
successfully put over 40 000 people on ARV treatment through the public health system in one 
year, however the WHO estimates that over 800 000 South Africans are in need of ARV 
treatment (WHO, 2005). In light of this, the ARV rollout has not progressed as fast as many 
desired with people dying while still waiting for treatment. Despite having 44600 people on 
antiretroviral treatment in March 2005 (WHO, 2005), activists were still not happy with the 
progress by the South African government. The health minister, Dr Manto Tshabalala-
Msimang, was accused of supporting AIDS dissidents and promoting garlic, beetroot and 
lemon as ideal nutrient supplements for people with HIV and AIDS. Tensions are thus high 
between the minister and AIDS activists. 
In response to the rising antenatal HIV prevalence in South Africa, Dr Manto Tshabalala-











the victims of HIV / AIDS and activists, felt that the minister was refusing to take responsibility 
and not taking the necessary actions to fight AIDS as illustrated below. 
Figure 6 TSHABALALA-MSI:\IANG REFUSES TO TAKE RESPONSIBILITY AND DOES NOT TAKE THE NECESSARY ACTION TO FIGHT 











CHAPTER 2: Methodology. 
The following outlines how the primary research for this dissertation was carried out, who was 
interviewed in the course of the research, and why exactly those individuals were of particular 
interest. 
Until now very little has been written about the Global Fund grant in Western Cape. Due to the 
limited availability of literature on the topic, it was impossible to write a paper without gaining 
direct access to documents and reports from the various stakeholders. This involved 
interviewing representatives of the selected stakeholders. Through this process, in-depth 
knowledge was gained on the subject and used in conjunction with various opinions, 
assumptions, theories and models, to formulate the basis of this dissertation. 
Interview Process and Case Data Collection 
Formal interviews were held, in the period July - September 2005, with II key individuals 
representing; the provincial AIDS council, the provincial ARV rollout team, and other key 
players. This was the primary research for this dissertation. 
The interviews represent qualitative research and were completed with no standard set of 
questions. The interviewees were encouraged to talk freely around key questions, which were 
uniquely developed for each interview. In order to obtain a collective view specifically 
regarding the success of the Western Cape rollout, all the interviewees were asked what factors 
they thought contributed to the success/failure of the Global Fund grant and the success/failure 
of the antiretroviral rollout. The responses to all these questions will be addressed in latter 
chapters of this research dissertation. 
Selection of candidates including field experience 
Key Stakeholders 
Country Coordinating Mechanism (CCM) 
Four representatives 











• The sub-CCM is the body that originally submitted the grant proposal to the Global 
Fund, and currently is monitoring the grant. The provincial AIDS council acts as the 
Global Fund sub Country Coordinating Mechanism (sub-CCM) in Western Cape. 
Western Cape Health Department 
Four representatives 
The principal recipient of the grant. 
• Dr. Fareed Abdullah, in charge of the Global Fund grant and deputy director of health in 
the Western Cape. 
• Three members of Abdullah's ARV management team and the ARV rollout. The ARV 
rollout team is the administrative team, which is in charge of the ARV rollout in the 
Western Cape. The team manages different aspects of the rollout, thus a few members 
were selected. 
• Dr John Frankish, the Global Fund Manager in Western Cape, was interviewed twice. 
Dr. Frankish is solely concerned with the objectives of the Global Fund grant. 
MSF and the Desmond Tutu Foundation 
Two members 
Partner organisations to the Western Cape Provincial Administration, (Principal recipient of the 
Global Fund grant). 
Interview Candidates 
Below is a list of the candidates interviewed for the primary research including a brief 
introduction to each interviewee. (A full list of members in the ARV rollout team and members 
of the sub-CCM can be found in the Appendix 1) 
Dr Fareed Abdullah: Deputy Director General: District Health Services and Programmes: Dr 
Abdullah has been involved in the public health domain for a long period of time and has been 
instrumental in the implementation of HIV/AIDS and related programmes in the Western Cape 
Province. Dr Abdullah has successfully implemented the Prevention of Mother to Child 
Programme throughout the province. He is one of the leading figures in the fight against the 
spread of the AIDS epidemic in the province and represents the Department of Health on the 











Dr John Frankish: Western Cape Global Fund Programme Manager: Dr. Frankish has also been 
involved in the public health domain for a long period of time and was party to producing the 
grant proposal, developing the project targets and outlining the performance indicators. Dr 
Frankish now works as a manager for the grant and is responsible for monitoring and evaluating 
the progress and results of the grant. Dr. John Frankish and Dr. Fareed Abdullah were key in 
the research as they represented the Principal Recipient of the Global Fund grant. 
Dr Keith C/oete: The Provincial Director for HIV/AIDS, Sexually Transmitted Infections and 
Tuberculosis. Western Cape Provincial Department of Health's Directorate ofHIV/AIDSITB is 
responsible for the ARV Programme in the Province. Dr Cloete has been working in public 
health in the Western Cape for many years. He has held many positions, and is currently in 
charge of the ARV programme in Western Cape. 
Dr Nevilene Slingers: Provincial ARV Programme Manager. Dr Slingers has been working for 
the public health sector for many years and has held various positions. She is currently 
managing the dedicated ARV clinics in Western Cape. Dr Slingers is also responsible for 
reporting on the ARV objective ofthe Global Fund grant. 
Ms Liezl Channing: Ms Channing works in the Western Cape Provincial Department of Health, 
where she is a member of the ARV rollout team. Channing is a Pharmacist and is in charge of the 
antiretroviral drug depot. 
Dr Andrew Boulle: Dr Boulle works in the Infectious Disease Unit at University of Cape Town. 
He has been involved with the MSF/PA WC projects in Khayelitsha. Dr Boulle has completed 
much research on ART and has been involved in writing the Global Fund applications. 
Dr Eric Goemaere: Head of Medecins Sans Frontieres (Doctors without Borders) in South Africa. 
Dr Goemaere was the first person from MSF who came to South Africa to start the collaboration with 
the Provincial Administration of Western Cape. He has vast experience from his work with MSF and 
has a very good knowledge of the Khayelitsha projects. 
Dr Pren Naidoo: Director ofHIV/AIDSITB in the Cape Town City Health Department. Dr. 











regarding the community based response of the Global Fund grant. 
Professor Gary Maartens: Lecturer University of Cape Town: Professor Maartens is employed 
by the Groote Schuur Hospital in Cape Town. Professor Maartens is the Head of Infectious 
Diseases Unit at the Hospital and is widely regarded as the country's leading HIV clinician. The 
Professor has been involved in numerous HIV/AIDS research projects and is also a lecturer as 
well as a Physician. In the Provincial AIDS Councillsub-CCM Professor Maartens represents 
Clinicians. 
Dr Ivan Toms: Director Cape Town City Health Department: Dr Ivan Toms founded Empiisweni 
SAC LA Clinic. This clinic is responsible for training and supporting Community Health 
Workers. Dr Toms became a National Co-ordinator for Service Development in 1990 and served 
as a Director for a number of Health Service delivery structures. Currently he is a Director of the 
Cape Town City Health Department where he is responsible for Primary Health Care. In the 
Provincial AIDS Councillsub-CCM, Dr. Toms represents Cape Town Unicity Health Services. 
Professor Robin Wood: Director of the Desmond Tutu HIV Centre, University of Cape Town. 
Prof Wood is in charge of the Desmond Tutu Foundation, which runs the community ARV clinic 
in Gugulethu. Prof Wood has extensive experience in ARVs, and acts as the Treatment Action 
Campaign's medical advisor. Prof Wood has provided vital research around ARV adherence. 
Constraints and bias of the research dissertation 
It is important to detail any potential factors that may constrain or bias of this research 
dissertation. 
The research has been conducted without any significant constraints. Access to information and 
relevant people in some cases proved a long process, but in the end all key individuals were 
interviewed with the exception of the Treatment Action Campaign's Chairperson, Zackie 
Achmat, who was not available to be interviewed during the period of which this dissertation 
was being researched. 
The fact that the research has focused on the strengths of the programme may mean that the 
interviewees were more likely to accept the invitation to be interviewed. 
It is important to highlight the author of this research dissertation is a Norwegian, and did an 5 











she is a foreigner may have made it easier to get hold of information, as locals are generally 
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In addition, the Western Cape has the highest GINI co-efficient reflecting an enormous 
difference between rich and poor compared to the rest of the country (Abdullah, 2005, p.247). 
The following statistics further highlight the environment of the Western Cape. The 
wealthiest 28% are mostly white South Africans, who use private medical care (Cummins, 
2002, p.49). According to the 2001 census, 18% of the population in the Western Cape are 
white, 54% are coloured, 27% are black African and 1 % are Indian/Asian (Statistics South 
Africa, 2003). The white and the coloured population mostly live in formal houses, while the 
population that lives in informal housing are mostly black Africans (Cummins, 2002, p.49), 
which indicates that more than 10 years after the end of the apartheid regime, wealth is still to a 
large degree related to skin colour. 
Furthermore, the Western Cape has a high degree of chronic, non-infectious diseases including 
diabetes, heart disease, hypertension, asthma, arthritis, psychiatric illness and a very high rate 
of Tuberculosis (Abdullah, 2005, p.247). Rates of alcohol and drug abuse, violence and traffic 
accidents are high compared to other parts of South Africa (ibid). Infant and child 
mortality rates are lower in Western Cape than the national average, and life expectancy is 
higher than the national average (ibid). More than 25 % of the population in Western Cape are 
unemployed, and the poorest live in informal housing in urban areas (Cummins, 2002, p.49). 
In some of the informal housing areas in Cape Town violence is common, and homicide is the 
biggest cause of death in men (followed by HIV / AIDS) (MRC et ai, 20051). 
mv prevalence by province among antenatal clinic attendees, South Africa: 
2002 -2004 
Province 2002 2003 2004 
KwaZulu-Natal 36,5 37,5 40,7 
Gauteng 31,6 29,6 33,1 
Mpumalanga 28,6 32,6 30,8 
Free State 28,8 30,1 29,5 
Eastern Cape 23,6 27,1 28,0 
North West 26,2 29,9 26,7 
Limpopo 15,6 17,5 19,3 
Northern Cape 15,1 16,7 17,6 
Western Cape 12,4 13,1 15,4 
South Africa 26,5 27,9 29,5 
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Figure II ESTIMATED HIV PREVALENCE RATES ADAPTED FROM PA we, 2005A AND DEPARTMENT OF HEALTH, 2005 
As can be viewed above the HIV prevalence in Western Cape (15,4 %) is lower than any 
other province and lower than the national average (29,5 %). Note however that the 
HIV / AIDS epidemic still affects an increasing number of people in the Western Cape (PA WC, 
2005a). The situation is expected to worsen as antenatal prevalence continues to rise 
steadily every year. HIV prevalence in the Western Cape rose from 1.2% in 1994 to 15.4% 
in 2004 (PA WC, 2005a). This number masks the huge disparities between different areas in 
the province such as Khayelitsha and Blaauwberg where the HIV antenatal prevalence rates 
are as high as 33% (Khayelitsha) and as low as 1.2% (Blaauwberg) (PAWC, 2005a). The 
Western Cape has thus several epidemics growing at different speeds within the province. 
Never the less, HIV/AIDS prevalence has been increasing steadily for over ten years, and is 
expected to continue to rise for the next years (Abdullah, 2005, personal comm., 23 Sept). 
Although it is not the largest single cause of mortality, apart from among children and 
women aged 15-49, the HIV epidemic is by many still believed to be the single largest health 
crisis facing the Western Cape at the present time (Abdullah, 2005, p.248). 
Prevention of mother-to-child transmission of HIV 
As discussed above, HIV prevalence rose steadily from 1990 in South Africa. Although 











1996/7 it took many years for it to be available in the public health system (Wood, 2005, 
personal comm., 9 Sept). Antiretrovirals were seen as too expensive for a public health 
system, and many questions were raised around their effectiveness. In spite of this the 
Western Cape started the first provincial government-run project to prevent mother-to-child-
transmission (PMTCT) of HIV in South Africa in 1999 (Slingers, 2005, personal comm., I 
Sept). In an interview Dr. Eric Goemeare quoted the project was secretly carried out at the 
time: 
"They had started PMTCT They wanted to start a program very low key because they didn't 
want the national to know about it. They had taken the initiative; the province has a lot of 
autonomy." (Goemaere, 2005, personal comm., 5 Aug) 
From January 1999 PMTCT was made available to HIV positive pregnant women In 
Khayelitsha3, The Health Department of the Provincial Administration Western Cape (PAWC) 
started the PMTCT programme in two midwife obstetric units in Khayelitsha (Abdullah, 
2005, p. 249). In 1999, the antenatal prevalence in Khayelitsha was standing at 20%, and 
at the time it was widely accepted that PMTCT could dramatically reduce the chances of 
HIV transmission (Goemaere, 2005, personal comm., 5 Aug). In the initial Khayelitsha 
PMTCT programme, AZT monotherapy was provided to HIV -positive pregnant women. 
Previously 3 out of 10 pregnant women would normally transmit their HIV infection to the 
child either during pregnancy, at birth or while breastfeeding (Abdullah, 2005, p. 249). In 
1999 AZT was reducing the risk of transmission of HIV from mother to child by about 50 per 
cent (ibid). 
3 Khayelitsha is a poor township 30km outside of central Cape Town. It has more than 500 000 residents 










HIV Prevalence by Health District: Western Cape 2000 - 2004 
District HIV PREVALENCE % 
2000 2001 2002 2003 2004 
Blaauwberg 0,6 8,2 4,4 1,2 
Cape Town Central 3,7 11,9 11,6 13,7 
Greater Athlone 6,8 8,9 10,1 16,4 
Helderberg 19,0 19,1 19,1 18,8 
Khayelitsha 22,0 24,9 27,2 33 
Mitchells Plain 5,4 0,7 4,0 6,3 12,9 
Gugulethu/Nyanga 16,1 27,8 28,1 29,1 
Oostenberg 5,7 14,5 16,1 14,8 
South Peninsula 5,9 6,0 9,3 10,8 
Tygerberg Eastern 5,1 6,1 10,4 7,9 12,7 
Tygerberg Western 7,9 12,7 8,1 15,1 
Bredasdorp/Swellendam 1,4 3,2 1,1 10 
Caledon/Hermanus 13 10,8 14,4 12,5 
Ceres/Tulbagh 6,2 9,4 7,5 10,5 
Worcester/Robertson 3,2 5,7 4,5 3,9 8,4 
Mamesbury 2,7 6,7 10,7 6,2 
Paarl 4,5 8,3 11,4 10,1 8,9 
Stellenbosch 7,1 8,5 8,5 17,8 
Vredenburg 8,9 9,0 10,0 13 
Vredendal 1,3 10,2 3,9 5,8 
Knysna/Plettenberg Bay 13,3 15,9 15,6 17,4 
Klein Karoo 0,8 7,8 5,4 5,5 
Mossel BaylLangeberg 7,0 6,8 13,3 12,5 
George 5,6 10,0 10,0 11,6 13,3 
Central Karoo 5,5 7,4 6,5 8,9 
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In addition to providing AZT to HIV -positive pregnant women, PA WC set up a voluntary 
counselling and (VCT) testing service at two maternity units. Follow-up care for the mother 
and the baby were set up at nine clinics in the area to provide advice to mothers about 
formula feeding (or exclusive breastfeeding) (Abdullah, 2005, p. 249). This was important 
as it ensured the follow-up checks on babies could be conducted to monitor for clinical signs 
of HIV where HIV could be definitively tested between the age of nine and 18 months 
(ibid). Previously in 1998, there were only 450 HIV tests in Khayelitsha, but with the expansion 
of the VCT service 22 000 HIV tests are now taken per year (2005) (Goemaere, 2005, personal 
comm., 5 Aug). 
The international non-governmental organisation (NGO), Medecins Sans Frontieres (MSF) (In English 
known as 'Doctors without Borders'), began supporting the Khayelitsha PMTCT programme in 
1999. This created the foundation of a partnership between MSF and PA we. MSF wanted to 
start a project in South Africa for three reasons (Goemaere, 2005, personal comm., 5 Aug). 
• Firstly, Durban 2000, the first international AIDS conference, would be conducted in 
South Africa and MSF was particularly interested in introducing issues around access 
to antiretroviral treatment at the conference. 
• Secondly, South Africa was, according to UNAIDS, the country with the highest 
number of people living with HIV / AIDS. 
• Thirdly, MSF perceived South Africa as being the country that was highly devoted in 
the fight against drug patents. 
MSF considered starting a programme in Alexandra Township (a township on the edge of 
Sandton, Johannesburg). However, neither officials in Alexandra nor the national government 
was interested in a program involving the use of antiretrovirals. Dr Eric Goemaere explains 
how, by chance, he came to discover the PMTCT programme in Khayelitsha: 
"In that time nobody sw,pected that there was a problem with antiretrovirals in this country. 
On the contrary there was a famous court case against pharmaceutical company, - to have 
access to generics. As a matter of fact, we discovered afterwards that anti-retrovirals were 
never part of the fight. It was for all the types of contracts, the essential contracts, - it was the 
first time in two years that the anti-retroviral were not part of the national protocol. 1 bought a 
ticket to go back to Europe, where 1 was prepared to say, 'well, sorry, we made a mistake '. But 
by chance 1 knew Zackie, the head ofTAC, by email, 1 had never met him, but bought a ticket to 











started something in Khayelitsha but I'm not totally sure, it looks like it's a rumour ... " so we 
came here, the next day to discover that they had started something in maternity ... They had 
started P MTCT. They wanted to start a program very low key because they didn't want the 
national to know about it. They had taken the initiative; you know the province has a lot of 
autonomy. And I came that day, discovered this programme, and I never left. That is what I've 
been doing. And that's the reason why Khayelitsha, it's the reason we came here. Since they 
developed the program ... " (Goemaere, 2005, personal comm., 5 Aug) 
The partnership with MSF allowed the PA WC to carry out pilot research before applying 
PMTCT through out the province. It was at times difficult, particularly when the national 
government was opposed to the use of antiretrovirals. PA WC and MSF gained great 
experience in the provision of antiretrovirals in a resource limited environment, showing that 
the reduction in mother-to-child-transmission (MTCT) was effective even in poor 
communities (MSF et aI, 2003). From 2001, the PMTCT programme expanded to more than 
300 antenatal and child health clinics in the Western Cape (Abdullah, 2005, p.249), and 
further research into the programme for HIV positive pregnant women resulted in a more 
effective prevention. Pregnant women and their babies in Western Cape after 2003, received 
more effective dual therapy (AZT + Nevirapine) (ibid),with infants being tested at 14 weeks 
and HIV positive infants being then referred for long-term antiretroviral treatment. In 2002, 
the transmission rate, using AZT monotherapy, was recorded at 8.9 per cent. Two years later, 
the results from HIV tests on babies born from HIV positive mothers who received dual 
therapy, showed a decrease in the transmission rate down to 5.5 per cent (ibid). In 2005 
pregnant women with a CD4 count of less than 200 were referred, and fast-tracked for 
antiretroviral treatment during and after their pregnancy (Abdullah, 2005, personal comm., 23 
Sept). Those women with CD4 counts above 200 received AZT from 28 weeks pregnancy, 
AZT and Nevirapine in labour and Combivir for seven days after the baby is born (Abdullah, 
2005, p.250). The infant was given one dose of Nevirapine and AZT syrup for seven days 
and the mother formula fed the baby. This combination has reduced HIV transmission rates 
down to below 2 per cent for the Western Cape (Toms, 2005, personal comm., 23 Aug). 
Pilot ARV projects 
In April 2000 the Provincial Administration of the Western Cape and MSF set up three 
HIV/AIDS dedicated clinics within Khayelitsha's primary health care centres (Kasper et ai, 
2003). These clinics were dedicated to offer treatment to the mothers and their infected children. 











stage of HIV infection (Goemaere, 2005, personal comm., 5 Aug). The treatment project was 
initiated to demonstrate that it was feasible and repeatable to treat HIV I AIDS with antiretroviral 
(ARV) drugs in a primary health care setting and in a resource-limited environment (Goemaere, 
2005, personal comm., 5 Aug). 
By introducing the treatment project it aimed to prove that developing countries could provide 
affordable HIV/AIDS care with low-cost ARV drugs (Goemaere, 2005, personal comm., 5 Aug). 
The three clinics: Site B Khayelitsha, Site C Nolungile and Michael Mapongwana, are located 
within community health centres in Khayelitsha. They provide other HIV/AIDS services along 
with ARV treatment, such as counselling, support, prophylaxis and treatment of opportunistic 
infections (PA WC et ai, 2005). The programme was initially almost exclusively run by MSF; 
however in recent years the PA WC has started gradually to take over (Slingers, 2005, 
personal comm., 1 Sept). The Western Cape will take over the clinics fully in 2007 
(Rosenberg, 2005a). The clinics account for a proportionally large share of people on 
antiretroviral treatment in the Western Cape (Abdullah, 2005, personal comm., 20 July). In 
July 2005, more than 2400 patients were on antiretroviral treatment at these three sites, 
about l!4 of the total number of people on ARV treatment in the Western Cape (Cloete, 2005, 
personal comm., 30 Aug). 
MSF has had a good relationship with the Infectious Disease Epidemiology Unit at the 
University of Cape Towns, which has produced much research about the results and successes 
of the MSF programme (Goemaere, 2005, personal comm., 5 Aug). Key progress in 
disclosure, adherence and improved quality of life made the MSF programme a well known 
successes (Goemaere, 2005, personal comm., 5 Aug). An increasing number of HIV tests were 
preformed in Khayelitsha; in 2004 there were 20 times more tests than in 1998. During 2004, 
20 000 HIV tests were performed; 25 % more tests than in 2003 (PA WC et aI, 2005). This 
figure indicates that 10% of the sexually active population in Khayelitsha had an HIV test in 
2004 (ibid). The three MSF clinics have also become more popular, with more consultations 
taking place as a result of more staff capacity. In 2004 over 40 000 consultations took place 
(ibid). The majority of the patients who started ARV treatment were women (70%) (Coetzee et 
aI, 2004a). The MSF programme has also been able to increase the CD4 count of the average 
patient. In 2002 the median CD4 count of each patient starting ARV treatment was a low 42 











were healthier when starting ARV treatment. ARV patients who were more open around 
disclosure to their partners were believed to have improved quality of life (Coetzee and 
Nattrass, 2004, p.5). Patients were also more open and willing to disclose their HIV status and 
research found that 72.6% had disclosed to a support group, while 82% had disclosed to one or 
more family member (Coetzee and Nattrass, 2004, p.4). Stigma attached to HIV/AIDS is also 
believed to have declined drastically since 1999 (Goemaere, 2005, personal comm., 5 Aug). In 
addition research has clearly proved that providing ARVs in the poor township were highly 
possible (Kasper et ai, 2003). 
Shortly after the introduction of the three MSF ARV clinics, the Desmond Tutu Foundation 
set up a clinic in Gugulethu (Wood, 2005, personal comm., 9 Sept). The foundation, like 
MSF, carried out vital research for PA WC (Cloete, 2005, personal comm., 30 Aug), proving 
that people in limited resources communities could access ART, and that they could have as 
high adherence to the ARV drugs as people in the developed countries (Orell et ai, 2003). 
PAWC entered into partnerships with at least six other NGO or research-based initiatives in 
public health facilities within the Western Cape (Cloete, 2005, personal comm., 30 Aug). By 
the end of 2003 the Western Cape Province had established ARV sites in Langa, at the G F 
Jooste, Groote Schuur, Tygerberg and Red Cross Hospitals in addition to the Gugulethu clinic 











CHAPTER 4: The Global Fund to fight AIDS. Tuberculosis and 
Malaria 
This research dissertation has so far discussed the exploration and existence of HIV/AIDS, 
HIV/AIDS policies within South Africa and the development / and prevention of HIV/AIDS 
particularly in the Western Cape. The following chapter introduces the purpose and structures 
of the Global Fund to fight AIDS, Tuberculosis and Malaria. 
AIDS, Tuberculosis and Malaria kill over 6 million people each year (Global Fund, 2005d). 
Without access to effective treatment and prevention, the numbers of people dying from these 
diseases are expected to rise dramatically. AIDS alone could kill more than 40 million people 
(UNAIDS, 2005). With the arrival of cheaper antiretrovirals many of these 40 million could 
live a normal life. The Global Fund was created to finance this striking turn-around in the fight 
against AIDS, TB and Malaria (Global Fund, 2005d). This chapter will focus on the Global 
Fund, and provide an understanding of how the fund operates. 
International agitation with the high numbers of deaths from AIDS, TB and Malaria started to 
accumulate in the new millennium. The Global Fund was set up to fight these diseases, and, 
following a call by United Nations Secretary-General Kofi Annan and others, to create a global 
health fund to increase dramatically the available funding to fight AIDS, TB and Malaria (UN, 
2001). The initial donor capital was pledged in May 2001, with both private and public 
stakeholders recommending the fund give out grants on the basis of received proposals (Global 
Fund, 2005e). The Global Fund to Fight AIDS, Tuberculosis and Malaria was constituted as an 
independent Swiss foundation in January 2002 and the Fund was fully operational by 2003 
(ibid). The first round of proposals. Round One, committed funding to 55 programmes in 36 
countries (Global Fund. 2005c). Since the first round of grants, there have been four succeeding 
rounds with round five in September 2005 being the most recent. To date, the Global Fund has 
committed US$ 4.4 billion in 128 countries to support the fight against AIDS, TB and Malaria 
(Global Fund,2005dt. 
According to the Global Fund 2004 Annual RepOlt, seven key structures shape the Global 
4 Figure taken on 21 November 2005 from the Global Fund's website www.theglobalfund.org for 











Fund: the Board. the Secretariat. the Technical Revie"v Panel, Country Coordinating 
Mechanisms, Principal Recipients, Local Fund Agents and the Partnership Forum (Global 
Fund, 2005a). 
The members of the Global Fund's Board consist of representatives from donor and recipient 
governments, non-governmental organizations, the private sector and affected communities. 
Representatives of the World Health Organization, UNAIDS, and the World Bank are also 
represented at Board meetings but without voting rights (Global Fund, 2005a). The Chair of the 
Board is United States Secretary of Health and Human Services Tommy G. Thompson, and the 
Vice-Chair is Dr Helene Rossert-Blavier, Director-General of the French non-governmental 
organization AIDES (ibid).5 A full list of current board members is found as an annexure. 
The Global Fund's Secretariat conducts all the day-to-day operations of the Global Fund. 
Approximately 120 professional and administrative personnel, whose main responsibilities 
include mobilising resources, managing grants and monitoring performance, staff it. The 
Secretariat is based in Geneva, Switzerland and its Executive Director is Dr. Richard Feachem 
(Global Fund, 2005a). 
When a country decides to apply for funding from the Global Fund, several key steps must be 
taken (Global Fund, 2005a): 
• Firstly, the grant proposal must be submitted via a multi sectoral Country Coordinating 
Mechanism (CCM). 
• Secondly, a multisectoral CCM should have representatives from public and private 
sectors, including government, non-governmental and faith-based organisations, people 
living with AIDS, TB or Malaria, bilateral and multilateral development agencies, and 
academic institutions. 
• Thirdly, a country can have a national CCM as well as it could have regional sub-CCMs. 
This is the case in South Africa, where the national AIDS council acts as the national 
CCM, while the provincial AIDS council acts as the sub-CCM. In such cases the grant 
proposal must first be submitted from the sub-CCM and then to the national CCM, which 
submits the proposal directly to the Global Fund. 











• Finally, the grant proposal should be in line with national strategies and stakeholders' 
different priorities. The goal is for the CCMs to have identified lack offunding for an area, 
which can be funded by the Global Fund. 
When the proposal arrives at the Global Fund it gets submitted to The Technical Review Panel 
(TRP), which is an independent body of international AIDS, TB and Malaria experts and health 
and development experts (Global Fund, 2005a).6 The TRP assesses the grant proposal for 
technical and scientific value based on global best practices. The TRP meets to review the 
proposals submitted for each funding round prior to the Board's meeting regarding the decision 
of which grants get funding. In fact, the TRP recommends to the Board proposals that are 
qualified for funding, which the Board either endorses or rejects. If the proposal is successful the 
Board initially commits funding for the full 5 years, however only funding for the first two years 
(phase one) is allocated. The board waits until the grant reaches phase two, before it funds years 
three to five (Global Fund, 2005b). 
After the Board's approval, the secretariat and the Principal Recipient (PR), who will receive the 
grant, engage in negotiations to determine the exact amount ofthe grant, set different performance 
indicators and targets, and decide on which conditions will have to be met before the two year 
grant agreement is signed (Global Fund, 2005a). Finally, the grant agreement is signed and the PR 
receives the funds to start the programme. The PR is now legally responsible for the programmes 
results, monitoring, evaluation, and financial accountability. The CCM oversees the 
implementation ofthe grant, reviews reports of the PR, and ensures local ownership. 
At milestones specified in the agreement, the PR sends a disbursements request to the Global 
Fund. In this disbursement request, the PR needs to demonstrate how the money has been spent 
and what targets have been reached. This usually is demonstrated by a six-month progress report. 
An independent agent (Local Fund Agent) then verifies the request (Global Fund, 2005a). This 
represents the foundation for the Global Fund's system of performance-based funding. 
Since the Global Fund has no staff outside its Secretariat in Geneva it has no way of verifying 
grant performance other than what is reported by the Principal Recipient. The Local Fund Agent 
6 A list ofTRP members can be found in the Global Fund's 2004 Annual Report, available at 











(LF A) is an independent agent, which is contracted by the Global Fund to assess the grant 
performance in a country (Global Fund, 2005a). The Global Fund contracts one LFA for each 
recipient country to assess the capacity of a PR to manage and administer the grant, manage the 
implementation of the funded programs and report on financial and programmatic progress. The 
LF A also verifies all disbursement requests, progress updates and reviews annual audit reports. 
The Global Fund 2004 Annual Report list the following agents contracted to operate as LF As: 
Chemonics International Inc., Crown Agents for Overseas Governments and Administrations 
Ltd., Deloitte Touche Tohmatsu Emerging Markets Group, KPMG International, 
Pricewaterhouse Coopers, the Swiss Tropical Institute of Chad and the United Nations Office for 
Project Services (Global Fund, 2005a). In South Africa, KPMG International serves as the LFA 
(Global Fund, 2006). 
Grant Performance 
Grant performance represents the cornerstone of the Global Fund's business model (Global 
Fund, 2005b). It is based on the principle that it will only fund programs that successfully 
contribute to the treatment and prevention of HIV I AIDS, TB and Malaria. The performance-
based funding covers all aspects of the Global Fund grant process, including proposal develop-
ment, grant agreements, regular disbursements and Phase Two evaluations (ibid). For the 
measurement of program success, all grant agreements include indicators and targets consented 
upon by the Principal Recipient and by the Global Fund. This is to ensure that the funding 
allocated to areas that are being managed and spent effectively. 
As mentioned earlier, the Global Fund generally approves grant proposals covering a five-year 
period. Grants are initially committed for the first two years of the proposal period. Continued 
funding to cover the remainder of the proposal period depends on satisfactory program 
performance and the availability of resources. The remainder of the grant covering years three 
to five is referred to as 'Phase Two' (Global Fund, 2005b). The Global Fund uses 'Phase Two' 
as a kind of checkpoint. Only grants with satisfactory performance measured against agreed 
targets for the first two years of the grant's life will continue to receive funding for the 
remaining three years (ibid). The Phase Two process was initiated in February 2004 for the first 
of the grants from round one (Global Fund, 2005a). All grants that approach their two year 











targets and indicators, renegotiate the grant agreement (Global Fund, 2005b). With the arrival 
of the -Phase Two' money comes another grant agreement with the Global Fund. Since the 
Phase two process is the renewal process of grants, grant performance decides further funding 
(ibid). 
Global Fund grants in South Africa 
Since the establishment of the Global Fund to fight AIDS, TB and Malaria as a financial 
institution, it has given out US$ 4.4 billion to 128 countries (Global Fund, 2005d) There have 
been five funding cycles, the first in 2003 and the most recent in September 2005. South Africa 
has received five grants from the Global Fund, three were from the first round of grants, 
'Round One', one from 'Round Two', and one from the third round of grants, 'Round 
Three'(Global Fund, 2006). 
A grant's life span is determined from the date the grant agreement is signed, and in the case of 
South Africa, the three grants from round one were signed August 8 2003, while the grant from 
'Round Three' was signed August 25 2004 (Global Fund, 2006). This means, the three grants 
given to South Africa from 'round one' were at their 'Phase Two' renewal point in the year 
2005. All three grants were initially declined for 'Phase Two' funding, however two of the 
grants are still in review, and their fate as of January 2006 uncertain. The grant from round two 
was signed on November 15 2005 (Global Fund, 2006). The five grants bear the following 
titles: 
1. Round One: 'Strengthening national capacity for treatment, care and support related to 
HIV and TB, building on successful behaviour change initiatives in South Africa (Soul 
City)' . 
2. Round One: 'Strengthening national capacity for treatment, care and support related to 
HIV and TB, building on successful behaviour change initiatives in South Africa 
(loveLife )' (only funded for the first two year, denied funding for the remaining three 
years). 
3. Round One: 'Enhancing the Care of HIV I AIDS infected and affected patients in resource-
constrained settings in KwaZulu-Natal'. 
4. Round Two: 'Strengthening National and Provincial Capacity for Prevention, Treatment, 











5. Round Three: 'Strengthening and expanding the Western Cape HIV/AIDS prevention, 
treatment and care programmes'. 
The South Africa's AIDS council acts as the Global Fund's South African Country 
Coordinating Mechanism (CCM) with the Deputy President and the Minister of Health as 
chairs (Global Fund, 2006). South Africa has requested $183,814,240.00 from the Global 
Fund. So far only $70,903,651.00 has been approved for the fist period of the grants (Phase 
One) (ibid). Further funding will depend on satisfactory performance in the 'Phase Two' 
review, and therefore only $55,350,967.00 has been disbursed by January 2006 (ibid). If 
additional grants are declined for 'Phase Two' funding the total amount over the five year 
period will be drastically reduced. 
A turbulent relationship with the Global Fund 
The grants to 'Soul City' and 'LoveLife', as classified above were completed without incident. 
However from the year 2002 to 2003 grant number three, the grant given to KwaZulu Natal, 
resulted in a stand off between the South African government and the Global Fund's secretariat. 
The cause of the stand off was due to the fact that K waZulu Natal had applied for funding from 
the Global Fund, without consulting the national government (Cullinan, 2003). The province 
had formed a sub-CCM, which had endorsed the proposal and submitted it to the Global Fund 
without consulting it with the national CCM. Note however, at the time that KwaZulu-Natal's 
application was submitted, there was no existing national CCM (Thorn, 2003). Later, the 
government declared that the South African National AIDS Council (SANAC) would act as the 
national CCM (Cullinan, 2002) By that time, the KwaZulu-Natal application had already been 
submitted- Note this application was supported by the KwaZulu-Natal sub-CCM consisting of 
the provincial government, the Durban Chamber of Commerce and Industry, non-governmental 
organisations and AIDS researchers - (Thorn, 2003). The Global Fund had accepted the 
proposal, and the grant project was due to receive funding in the first round of grants (Thorn, 
2003). Only after the grant had been accepted did the national CCM members, in particular the 
Minister of Health, Dr. M Tshabalala-Msimang, become aware of the multi million dollar grant 
that had been awarded to KwaZulu Natal (Cullinan, 2003; Jubasi, 2003). 











KwaZulu-Natal story caused much unrest within the South African AIDS activist community, 
with the Treatment Action Campaign (T AC) threatening legal action. There were many articles 
written in the media about this matter. Some argued that constitutionally, health care is a 
concurrent function of national and provincial government; therefore legally, KwaZulu-Natal 
should be able to raise money to fund its own priorities. 
This controversy resulted in a one-year delay for the grant, and eventually, in August 2003 all 
three grant agreements from 'Round One' to South Africa were signed were signed by the 












CHAPTER 5: Grant SAF-304-G04-H - 'Strengthening and expanding 
the Western Cape HIV/AIDS prevention, treatment and care 
programmes' 
The Western Cape Department of Health has been highly committed to HIV/AIDS prevention, 
treatment and care at times when the national government was filled with scepticism. In particular 
when the government was claiming ARVs to be toxic and were opposed to universal treatment. The 
Western Cape Province wanted to expand access to antiretroviral treatment, however with no 
support from governmental funds PA WC was forced to look for external funding. The province 
submitted its first proposal to the Global Fund in 'Round Two' but the grant was unsuccessful 
(Boulle, 2005, personal comm., 10 Aug). At the time of this application there was massive conflict 
between the national government, the health minister, Dr. Manto Tshabalala-Msimang, and the 
Global Fund Secretariat surrounding the KwaZulu-Natal grant. Dr. Andrew Boulle, who was 
involved in writing the 'Round Two' application, explains why he thought the proposal failed 
to get funding: 
'J think there were actually seventeen South African proposals in that round, and because the 
South African CCM didn't follow procedure, they were all rejected on that . . ,. The process was 
always political. The reason we all knew why 'Round Two' hadn't been considered was 
because of the relationship between the South African CCM and the Fund. .. and J think that the 
Fund was very encouraging to resubmit '(Boulle, 2005, personal comm., 10 Aug). 
Dr Boulle suggests that the Western Cape knew that the proposal was rejected on political 
grounds, and on the encouragement from Dr Richard Feachem, the executive director of the 
Global Fund, they improved and resubmitted the proposal. Coincidently Dr Feachem was in 
South Africa in April 2003 to meet with the South African Government to solve the issue 
around KwaZulu Natal with the aim to agree on and sign the grant agreement (Goemaere, 2005, 
personal comm., 5 Aug), so that the programme could start running. Despite Dr Feachem's 
hope to resolve the KwaZulu Natal story, the issue remained unsolved (Cullinan, 2003). By this 
time the MSF/PA WC project in Khayelitsha already was up and running, and according to Dr 
Eric Goemaere, it sparked Dr Feachem's interest: 
Khayelitsha becoming a well-known programme, mainly after the publication by WHO, they 
did a sort of best practice series, and Khayelitsha was one of the first to be published. So 
Feachem was interested to come for a visit, and asked for a visit. So he was invited here and J 











against the national, and I'm sure Feachem used the Western Cape against national. It was 
very well known that he was goingfrom one province to another. No the matter offact, when he 
came to visit here he came to South Africa to sort out the KwaZulu Natal story ... he told me 
that he thought this is a misunderstanding, let's take a ticket -flight ticket and spend three days 
talking face to face with people, it must be, it's not possible, it's a misunderstanding and we 
saw Richard Feachem here absolutely, absolutely ... he was furious. He had lost four days of 
his life for nothing - you know. In fact, he didn't realize that South Africa, that it was such a 
mission and that he hasn't achieved anything since then because it was being blocked so he 
was so pleased to find here Fareed and the whole team that was ready and keen to start 
something and he needed something that was already working you know. ' (Goemaere, 2005, 
personal comm., 5 Aug) 
The effort of work that went into this second application was impressive; it was a much more 
inclusive and holistic proposal, involving a number ofNGOs. 
'And honestly today I have never seen a public administration working like the wtry they work. 
I was called there 10 0 'clock at night because they have to finalize the papers and those guys 
were working 'til 12 0' clock at night. I mean the public, civil servants? Not in that many 
places, and that isfantastic, you know?' (Goemaere, 2005, personal comm., 5 Aug) 
In May 2003, the Western Cape Provincial Department of Health applied for funding from the 
Global Fund to Fight AIDS, Tuberculosis and Malaria (PA WC, 2003a). The application was 
successful and the grant was approved on the Global Fund's sixth Board Meeting - Chiang Mai, 
Thailand, 15-17 October 2003 (Global Fund, 2005f). This initiated the grant negotiations with 
the secretariat with the final grant agreement being signed on 25 August 2004 (Global Fund, 
2006). The arrival of the first disbursement of funds came a little time later and on October 20 
2004 the Western Cape Premier, Marthinus van Schalkwyk, announced the breakthrough for 
the province. The Western Cape Provincial Department of Health had received the biggest 
grant so far given to a provincial department (PA WC, 2003c). The grant by the Global Fund 
was a five-year programme to strengthen and expand the province's comprehensive HIV/AIDS 
programme, with a total value ofthe five-year grant programme of US$66,5 million. 
The five year programme is divided into four objectives: 
1. To strengthen the ARV treatment programme through the expansion of the provision of 
antiretroviral treatment, providing for ARV treatment in Phase One of the Grant at six 











2. To strengthen the current prevention effort by expanding a peer education programme 
among youth at secondary schools. 
3. To strengthen palliative in-patient and home-based care services by expanding the 
already existing network of hospice facilities and their linked home-based care services. 
4. To strengthen community-based responses to the epidemic through the development 
and implementation of local support projects within specified focus areas. 
(Global Fund M&E Plan. Western Cape Department of Health 2004d) 
Each of the four areas were divided as follows and comprised of a total value of U SO 
15,509,356 for the first two years: 
The four objectives of the 
Global Fund grant: Year 1 Year 2 Total 
(USD) (USD) (USD) 
ARV Treatment! Operational 
Research 3,560,083 5,607,623 9,167,706 
Peer Education 876,928 932,653 1,809,581 
Palliative Care 858,857 1,586.429 2,445,286 
Community-Based Response 866,714 1,220,069 2,086,783 
Total 6,162,582 9,346,774 15,509,356 
Figure 14 THE FOlJR OBJECTIVES OF THE GLOBAL FUND GRANT (ADAPTED FROM THE GLOBAL FUND WORK PLAN, WESTERN 
CAPE DEPARDIE:-IT OF HEALTH, 2004c) 
The first objective: antiretroviral treatment received almost 2/3 of the total grant. It has therefore 
been the main focus of this dissertation. To further understand this objective it is important to note 
that the ARV treatment component in the grant agreement was split into five main areas: 
1. Staff and administration 
2. IT infrastructure 
3. Recourse centre 
4. ARVDrugs 
5. ARV treatment 
For the purposes of this dissertation the latter two components are discussed further below. 
ARV drugs 
The Western Cape is fortunate to have a comparatively well functioning health sector, however 











before the grant agreement with the Global Fund was signed (Abdullah, 2005, personal comm., 
19 July). KPMG had previously completed an audit of the medical depot, and demanded 
changes. The solution was to set up a new, separate medical depot for antiretrovirals (Abdullah, 
2005, personal comm., 19 July). This provided a quick short-term solution to the problem, 
while the long term solution would be to improve the existing depot. The PA WC set up an 
ARV depot in six weeks, which was enough time to satisfy KPMG and get the grant agreement 
signed (Abdullah, 2005, personal comm., 19 July). 
The ARV depot to this day functions very well, and has never had any major stock shortages on 
ARVs (Channing, 2005, personal comm., 25 Aug). It is important to note that the Western 
Cape is fortunate in having local suppliers, which enables them to purchase antiretroviral drugs 
monthly (Channing, 2005, personal comm., 25 Aug). The depot keeps three to four months of 
stock, which has a value ofR7, 5 to RIO million (Channing, 2005, personal comm., 25 Aug). 
The easy access to ARVs for clinics has insured that the sites never run out of ARVs, while the 
same cannot be said about the general medical depot. Eric Goemaere, who runs the MSF 
programme in South Africa, very much appreciates the ARV depot (Managed by Liezl 
Channing) . 
.. We have a straight management line with direct contact to one person to whom to decide ... 
and if you have a problem, then Liezl (Channing) is available - there's no drugs or the drug's 
gone. Because other times you have to go via, via, via, and you don't get an answer there for 
four weeks, that's for sure. It makes a huge difference" (Goemaere, 2005, personal comm., 5 
Aug) 
There is no question that the specialised ARV depot has contributed to the success rate of the 
Global Fund grant. One can always question the solution as a short-term solution which has 
been highly criticised by some who claim that the resources should have been used to 
strengthen the functioning of the general Cape Medical Depot that houses all other medicines 
and diagnostics procured by the Department of Health, instead of unnecessarily building a new 
infrastructure, hiring new staff and creating more bureaucracy to manage the HIV I AIDS 
treatment programme. The separate ARV depot has insured that ARVS7 were available at all 
ARV clinics at any given time, making clinics able to provide the life saving medication. It 











would "karly he beller if i'A we inc.orpor~ted the AI{ V depot into the general depot, and made 
sure that all drugs, not onl) ARVs were avai lable to all clinics at an) given time , 
The picture below is from the ARV ocpo(s l1"t days. when thev were ,till wa iling for the 
pm!",r rdrigeratm", hence the homlwed <""" from Coca Cob' 
H~ LII" l ~ .\11\' DC"'T (L. CH,""'G, U'-'"L ]I D" , •• J'''.N L OF lH~ PkO"'CHl ,\" .'''''ST.'TIO~ 0/ THE WEST,"' 
(" •.• lOO~) 
ARV Treatment Sites 
InLhe grant projee-('s liN two ycars, til<: Global Fund provides funds lor ARV Treatment si tes 
wiLhin the metropolitan region of Cape Town. The five ARV sitcs that received Global Fund 
money were: (CHC reters to communi!} hea lth clinic) 
• Gugulelhul j lC 
• Khaye litsha: Site Il CI IC 
• Kha)clitsha: Site C CHC 
• Khayclitsh.a: Michael Mapongwana CHC 










All the five clinics were within the greater Cape Town area and were co-run by an NGO. The 
clinics were all pilot research sites prior to the Global Fund money. It was a deliberate choice 
from PA WC to put the money where they knew it would work (Abdullah, 2005, personal 
comm., 20 July). It would be easier to have a successful programme that could build on 
something, i.e. upscale as opposed to starting from scratch (Abdullah, 2005, personal comm., 
20 July). After the rocky start of the KwaZulu-Natal grant, it was increasingly important for the 
Global Fund and the Western Cape that this project was a successful grant. By choosing 
already well-functioning clinics with around 1000 people on ARV treatment, and by planning 
the upscale in great detail, Western Cape insured themselves against failure, and had perhaps 
the best foundation for a successful grant. 
The success of the ARV component of the grant has been measured by the cumulative number 
of patients on ARV treatment at each ofthe ARV Treatment Sites. 
Global Fund Grant Objective 1: ARV Treatment Year 1 
Intended results/targets in year 1 
Key Indicators Quarter 1 Quarter 2 Quarter 3 Quarter 4 
Gugulethu 410 560 710 860 
Cumulative Khayelitsha Site B 490 580 670 760 
number of 




treatment at 5 Michael Mapongwana 375 450 525 600 
sites Masiphumelele 95 170 245 320 
Total 1765 2230 2695 3160 
Figure 16 GLOBAL FUND GRAND OBJECTIVE I: (ADAPTED FROM THE GLOBAL FlJND MONITORING AND EVALUATION PLAN, 
WESTER:'; CAPE DEPARTMENT OF HEALTH, 2004D) 
As seen in the above table, each clinic was given specific targets. The number of patients 
starting on ARV treatment, and the number of patients discontinuing treatment are also 
presented in progress reports (Frankish, 2005, personal comm., 22 July). The report includes 
targets of how many new patients should start treatment in relation to achieving the total figures 
of people on ARV treatment. The focus of this dissertation is on the total target numbers not 
each segment. 
The grant money from the Global Fund only arrived in October 2004. The province initially 











agreement with the Treasury provided bridging finance, enabling the program to start early on 1 
July 2004 (Frankish, 2005, personal comm., 22 July). Once the money from the Global Fund 
arrived, the programme start date was made retrospective to coincide with the actual 
programme start date (Frankish, 2005, personal comm., 22 July). Thus the first year of the grant 
is from 1 July 2004 - 30 June 2005. Thus the first year of the grant SAF-304-G04-H is from 1 
July 2004 - 30 June 2005. 
The following is a brief account of each clinic: 
Gugulethu CHC Site: 
The Gugulethu CHC has been providing ARV treatment to infected people since September 
2002 (Wood, 2005, personal comm., 9 Sept). The clinic is co-funded by CRUSAID and other 
organisations (Wood, 2005, personal comm., 9 Sept). It is managed and run by PA WC and the 
Desmond Tutu Foundation, led by Prof. Robin Wood. The number of patients on treatment by 
the end of June 2004 had reached 289. 
The Global Fund grant provides for the continuation of the ARV treatment for those original 
289 patients who started treatment prior to the start of the Global Fund project in Gugulethu. In 
addition the grant provides supplementary personnel, ARV medicines and laboratory 
investigations. A new HIV/AIDS clinic building, funded by the Western Cape Department of 
Health, was completed at Gugulethu CHC in the fist year of the Global Fund grant. Additional 
funding provision from the Global Fund grant also supported the purchase of furniture and non-
medical equipment for the new clinical building. A total of 825 patients were on ARV 
treatment at Gugulethu in the end of June 2005. Gugulethu fell 35 patients short as the target 
was to have 860 patients on treatment. The reason for Gugulethu's slow upscale is related to an 
extra required building being set up (Slingers, 2005, personal comm., 1 Sept). Once the 
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Figure 17 PATIENTS ON ART IN GliGULETHU CHC: SOURCE: CLOETE, HEALTH DEPARTMENT OF THE PROVINCIAL 
ADMINISTRATION OF THE WESTERN CAPE, 2005 
Masiphumelele Site - Fish Hoek 
The Masiphumelele site is a collaboration of research projects involving the Chris Hani 
Baragwanath Hospital, the National Health Laboratory Service, the University of Stellenbosch, 
the University of the Witwatersrand, and the University of Cape Town. It is supported by the 
Provincial Health Departments of the Western Cape. The staff, monitoring and research costs 
of the project are funded by the National Institute of Health, USA. The clinic was originally set 
up in 2004 (Wood, 2005, personal comm., 9 Sept). 
The Global Fund grant provided programme furniture and non-medical equipment for a new 
building. No additional personnel are funded by the Global Fund. The number of patients on 
treatment by the end of June 2004 was 27, and The Global Fund programme provided 
continuation of ARV treatment of those 27 patients who had started treatment prior to July 
2004. The target was to have a total of 320 patients on ARV treatment after one year with the 
Global Fund project, and in June 2005 a total of 222 people were on treatment, well below 
target. The challenge in Masiphumelele has not been related to infrastructure and staffing, it 
has, according to Dr. Nevilene Slingers, rather been a question of high disapproving stigma in 
the community. Masiphumelele is a very small community compared to Khayelitsha, and 
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Figure 18 P A TIE~TS ON ART IN IVlASIPHllMELELE CLINIC. SOURCE: CLOETE, HEALTH DEPARTMENT OF THE PROVINCIAL 
ADMINISTRATIO~ OF THE WESTERN CAPE, 2005 
MSF sites in Khayelitsha: 
Medicins Sans Frontieres (MSF) runs three of the five clinics that are receiving funding from 
the Global Fund. The three clinics have been providing ARV treatment since 2001 in 
Khayelitsha.8 The Global Fund grant provides additional staff, ARV drugs, laboratory services 
and non-medical equipment such as furniture in all three clinics. MSF funds 300 patients at the 
Michael Mapongwana CHC, while the Global Fund funds the rest. A total of 2272 patients 
were receiving ARV treatment at these three sites in the end of June 2005. 
Khayelitsha Site B CHC: 
The Khayelitsha Site B CHC has been providing ARV treatment since 2001. The number of 
patients on treatment by the end of June 2004 was 422. The Global Fund programme provided 
continuation of ARV treatment of those 422 patients who had started treatment prior to July 
2004. The target was to have a total of 760 patients on ARV treatment after one year with the 
Global Fund project. In June 2005 a total of 880 people were on treatment. In its first year Site 
B exceeded its target by 120 patients. 
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Figure 19 PA TlEIliTS Olli ART IN SITE B KHA YELITSHA. SOURCE: CLOETE, HEALTH DEPARTMElliT Of THE PROVINCIAL 
AOMlllilSTRATlOIli Of THE \VESTERN CAPE, 2005 
Khayelitsha Site C Nolungile CHC 
The Khayelitsha Site C CHC has been providing ARV treatment since 200 l. The number of 
patients on treatment by the end of June 2004 was 359. The Global Fund programme provided 
continuation of ARV treatment of those 359 patients who had started treatment prior to July 
2004. The target was to have a total of 620 patients on ARV treatment after one year with the 
Global Fund project. In June 2005 a total of612 people were on treatment. In its first year Site 


















Figure 20 PA TlEIliTS ON ART IN NOLlJNGILE CHC. SOURCE: CLOETE, HEALTH DEPARTMENT OF THE PROVINCIAL 











Khayelitsha: Michael Mapongwana CHC Site 
The Michael Mapongwana CHC has been providing ARV treatment since 200l. The number of 
patients on treatment by the end of June 2004 was 340. The Global Fund programme provided 
continuation of ARV treatment of those 340 patients who had started treatment prior to July 
2004. The target was to have a total of 600 patients on ARV treatment after one year with the 
Global Fund project. In June 2005 a total of 780 people were on treatment. In its first year 
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Figure 21 PATIENTS ON ART IN MICHAEL MAPONGWANA CHC. SOURCE: CLOETE, HEALTH DEPARTMENT OF THE PROVIN-
CIAL AD:\IINISTRA TlON OF THE WESTERN CAPE, 2005 
The 5 Global Fund ARV sites combined 
As a whole the Global Fund grant has managed to meet or exceeded its ART targets. The 
number of new patients who started on ARV treatment with Global Fund money has constantly 
performed well. Discontinuing rates, as people stop taking the medication, move or die will 
naturally affect the cumulative number of patients on ARV. The grant has managed to hit its 
targets, despite some clinics performing under target. For the first year of the Global Fund grant 
the target was to have 3 160 patients on ARVs at the 5 funded sites. The actual number was 
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Figure 22 PATIENTS ON ART IN ALL 5 SITES (CLOETE, HEALTH DEPARTMENT OF THE PROVINCIAL ADMINISTRATION OF THE 
WESTER!" CAPE, 2005) 
The numbers shown above are total accumulative numbers, stating the total number of patients 
on ARV treatment at the given times. In the grant agreement those figures are based on the fact 
that 465 new patients start treatment each quarter. The numbers below tells how successful the 
grant has been in putting new patients on treatment in the first year of the grant. Overall the 
target was to start 1860 patients on treatment within a year. The actual result was 2216, clearly 
exceeding the target. It is interesting to note on the chart that there was a decline in new 
patients during the summer/Christmas period, which is most likely due to people leaving for 
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Figure 23 ~lJMBER STARTED ON TREATMENT AT 5 GLOBAL FliND SITES: (FRANKISH, HEALTH DEPARTME:'IIT OF THE 
PROVI:'IIClAL AO\fI;';ISTRA TlON OF THE WESTERN CAPE, 2005) 
The total number of people on treatment at the five sites after one year will depend on how 
many patients discontinued treatment. During this period 334 patients stopped the ARV 
treatment at the sites,and these numbers were not built into the targets ofthe Global Fund grant, 
however they affect the overall performance as measured in total numbers on treatment. The 
chart below gives an account of how many patients discontinued treatment. Suspected reasons 
for discontinuing could be death, dislike of the ARVs (i.e. high toxicity of the drugs), or 
mobility (patients moving back to rural areas like Eastern Cape). Such reasons are not included 
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Figure 24 NllMBER DISCONTlNlIED ON TREATMENT JlILY 2004 - JlINE 2005 (FRANKISH, HEALTH DEPARTMENT OF THE 
PROVINCIAL ADMINISTRA T10N OF TilE \VESTERN CAPE, 2005) 
Despite the discontinuing rates of people on treatment the grant still exceeds its targets, for the 
first year, both when it comes to new patients on ARV treatment, as well as total number of 
people on treatment. Based on this the overall ARV component of the grant is successful. 
The general rollout in Western Cape 
The ARV treatment roll-out in the Western Cape is considered to have so far been a highly 
effective and successful programme (Abdullah, 2005; Coetzee et ai, 2004a; Kasper et ai, 2003; 
Orrell et ai, 2003, WHO, 2003) as defined by its capacity to quickly and effectively treat a 
substantial number of people living with HIV/AIDS while yielding measurable reductions in 
AIDS-related morbidity and mortality (WHO, 2003).The Western Cape province has managed 
to put people on ARVs faster than any other province. The well running pilot projects in 
Western Cape gave the province something to build on. 
Following the South African National Cabinet's decision of 19 November 2003 to 
implement and fund a national HAART intervention in all provinces, and along with the 
promised grant from the Global Fund, the antiretroviral roll-out began gradually in 2004 
(Cloete, 2005, personal comm., 30 Aug). The Western Cape as per December 2006 reaching 
an estimated 65% of those in need of ARV treatment in the province (F. Abdullah sited in 
Herman, 2006). This figure coincides with the ASSA AIDS model, which PA WC has used 
when planning the need of ARV treatment (Abdullah, 2005, personal comm., 23 Sept). 
Nationally in South Africa, it is estimated that only 10% of those in need of treatment have 
access to ARV treatment (F. Abdullah sited in Herman, 2006). This supports the view 
reflecting the success of the Western Cape. Other urban areas like Johannesburg and Pretoria 
have had a slower start, but have since caught up in total numbers (Cloete, 2005, personal 
comm., 30 Aug). However, as the prevalence rate is much higher in Gauteng, they will have 
more people in need of ARV treatment than Western Cape has. 
The five Global Fund sites are a part of a planned total of 44 ARV sites by March 2006. In 
August 2005 there were 39 ARV sites operational, and as of end of July 2005 there were 
10451 people on treatment (Cloete, 2005, personal comm., 30 Aug). The Western Cape has 
managed to upscale quite successfully, and are beating their own targets. The goal was to 











and in August 2005 the programme enrolled an average of 800 new patients onto treatment 
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Figure 25 PATIENTS ON ART IN THE WESTERN CAPE MARCH 2004 - JULY 2005 (CLOETE, HEALTH DEPARTMENT OF TilE 
PROVINCIAL ADMINISTRATION OF THE WESTERN CAPE, 2005 
Dr. Gary Maartens has categorised the ARV rollout in Western Cape as like a 'military 
operation' (Maartens, 2005, personal comm., 4 Aug). PAWC has, accordingly to Dr. Keith 
Cloete, the HIV/AIDS director in PAWC, followed a very detailed and well-planned 
structure: 
"Firstly ... a site selection. Then a staffing estimate per site: so many doctors, so many nurses ... 
Then we did a projected patient enrolment at each site, so we build up ... so many people will be 
there in March, so many in April, so many in May and June, and we did it month by month. We 
then work out how much will it cost drug-wise ... how much will it cost for the people and lab-
wise for all the investigation and how much will it cost month per month to pay for all the staff 
for every site that we had, we put all of that into one big business plan and we got about ... we 
had eventually 25 - 30 different excel spread sheets per site to put this whole thing into 
perspective to kick out one budget schedule. It was actually not just a budget schedule, it was 
actually just all a month by month plan of enrolment, staff, we knew exactly which month which 
nurses are going to start ... exactly how many patients per site, exactly how much we were 
going to pay for the lab. So it eventually became a detailed month per month plan, which you 
can equate to a kind of military operation because it got to that level of detail and we roughly 
stuck to all those targets ... " (Cloete, 2005, personal comm., 30 Aug) 
PA WC had a good working knowledge of operational issues having experience in working 
with antiretrovirals, both in the MTCT programme and the pilot ARV sites. Thus the Western 
Cape developed a strategy for the antiretroviral rollout. On the basis of the experiences from 











2005, personal comm., 20 July; Cloete, 2005, personal comm., 30 Aug). The decision on 
where to place the ARV sites was based on a combination of geographical access and high 
HIV prevalence areas (Cloete, 2005, personal comm., 30 Aug). The PA WC annually 
provides detailed information on the antenatal survey, showing clearly which areas have 
high prevalence compared to others with low prevalence (Cloete, 2005, personal comm., 30 
Aug). An alternative method of providing ART would be to open ARV sites in the high 
prevalence areas, such as urban areas like Khayelitsha and Gugulethu, and to concentrate 
on a model based on the antenatal survey. This has not according to Dr Cloete taken place: 
'It doesn't matter where you are within the province, you going to have geographic access to a 
site... the question is not about where the antenatal prevalence site is, its about saying how do 
you get geographic access across the province and ... to get a balance right between 
decentralisation and centralisation so that you provide reasonable access from wherever you 
are in the province. That was actually the determining factor of where the sites were' (Cloete, 
2005, personal comm., 30 Aug) 











CHAPTER 6: Success factors 
The Western Cape Global Fund grant has, as seen in the previous chapter, been highly 
successful in meeting the targets set. The overall rollout of ARVs in the Western Cape has also 
been described as a success by all interviewed. The same success factors could be attributed to 
both the Global Fund grant as well as the general rollout of antiretrovirals. This chapter will 
look at the success of the ARV component of the Global Fund. It will try to summarize the key 
factors that have contributed to the success. 
Low prevalence I Urban setting 
The Western Cape had an advantage that enabled them to progress faster than other provinces 
when it comes to ARV treatment. Many of the interviewees have highlighted the following 
factors as being major contributors to the successful ARV treatment rollout, both in the five 
clinics supported by the Global Fund, and in the other ARV clinics in the Western Cape. 
The first factor was that the province had a good health structure with tertiary hospitals, mobile 
clinics and district and community clinics. In addition the Western Cape already had a well 
functioning health system, with good access to health care. 
Secondly, the province is predominantly urban, with the majority of the population living in 
and around Cape Town. This makes it easier to concentrate on a fewer number of clinics. 
Thirdly, Western Cape has the lowest HIV prevalence rate in South Africa, thus the infection 
rates were lower, and thus more manageable. 
Fourthly, Western Cape is fortunate in being able to attract committed health professionals as 
Cape Town is known to be a beautiful city where people would like to live. 
Thus the aforementioned factors have allowed the Western Cape Province to make ARV 
treatment more manageable than in other less fortunate provinces. 
Timing 
Timing has played a crucial factor in the success, as the Western Cape was lucky to get a 
partnership with MSF in Khayelitsha at a time when national policy was opposed to the use of 











would have taken Western Cape a much longer time to develop the expertise that MSF acquired 
in Khayelitsha, and hence the Global Fund programme and the general rollout wouldn't have 
these advantages, and thus the programme might not have been successful. 
Timing also played a vital role in the arrival of the Global Fund grant. The grant coincided with 
the national rollout, which allowed the Western Cape to use the Global Fund money to expand 
the rollout and go for a spread out model, reaching more areas than they would have reached 
without the grant money. The provincial administration could plan for the rollout and make the 
Global Fund five sites a part of the bigger plan. There was no need to produce one detailed plan 
for the Global Fund ARV sites and separate one for the national money; it could all be planned 
together. This saved the management time and recourses and it ensured a holistic plan where 
the Global Fund sites were five selected sites out of the planned 44 sites. 
Had the Global Fund grant been approved in round two, and not in round three, then the grant 
would most likely have arrived at a time when the South African national government was 
opposed to free ARVs through the public health system, which would probably have made it 
more difficult to achieve success with the program and would most likely of raised more 
controversy around the topic. 
Experience through partnerships 
A key to the success of both the Global Fund supported ARV programme and the general 
rollout of ARVs in the Western Cape has been successful partnerships between PAWC and 
independent organisations. Two partnerships have been extremely important for the success 
of the Global Fund grant: 
• Medicins Sans Frontieres (Khayelitsha) 
• Desmond Tutu HIV Centre (Gugulethu) 
These two partnerships were particularly vital in the early days of the rollout when national 
policies were against public ARV treatment. These organisations produced vital research on 











was as good as in developing countries.9 
The partnerships, especially the MSF partnership on prevention of mother-to-child 
transmission of HIV, which started as early as in 1999, gave the Western Cape Department 
of Health an opportunity to gain vital experience in managing ARVs in a resource poor 
communities while the national debate was raging. This has been categorised as a smart 
move by the provincial administration. 
"Fareed (Abdullah) was clever enough putting this totally as private research, but in fact in 
governmental site. So in fact, in a way he protected himself from the rage of national. So he 
could always claim "oh, no it is not us" But at the same time he could benefit from the 
experience" (Goemaere, 2005, personal comm., 5 Aug) 
Although antiretrovirals were available in the private health sector at the time, PA WC had 
limited experience with implementing and managing ARV treatment, and it would be a fair 
comment to say that they would not have been able to gain the same level of experience 
without the MSF partnership in Khayelitsha. 
"And MSF has helped. Great help of course ... 1 mean the Khayelitsha pilot and showing that it 
worked and dealing with all the problems ... and MSF involvement in Khayelitsha ... putting out 
papers and things that showed that they were able to keep the compliance and all that so it 
wasn't as dangerous for people to worry about, has also strengthened our hand at an early 
stage". (Toms, 2005, personal comm., 23 Aug) 
"I think they would have been able to have significant pilot sites operational, but not to the 
scale. Not as early as 200012001, not at the scale of Khayelitsha, and not in Khayelitsha, 
because 1 mean the MSF involvement was the key to starting a lot earlier before any other 
organisations got going a bit later when more funding became available etc. 1 think 
Khayelitsha as a surface context was a very challenging surface context ... and not many other 
NGOs would have chosen to start there ... and 1 think having a partner with a strong political 
and advocacy vision was important at the time, given the political context". (Boulle, 2005, 
personal comm., 10 Aug) 
When the pilot sites initiated ARV treatment both in Khayelitsha and in Gugulethu, PAWC was 
able to gain uniquely different experiences, from two different communities with high HIV 
prevalences. Khayelitsha is a more mobile community, with great influx of patients from 
Eastern Cape, while Gugulethu is a much more stable community (Slingers, 2005, personal 
9 See Coetzee et al (2005), Coetzee et al (2004), Kasper et al (2003), Orrell et al (2001), Orrell et al 











comm., I Sept). The two projects also operated with different counselling models and thus 
these experiences gave PA WC great insight in ARV discontinuing rates. In July 2005 PAWC 
had not decided on which model provided the pest result (Frankish, 2005, personal comm., 22 
July). 
From 2000/200 I the Western Cape developed other partnerships on ARV treatment. The 
partnership with the organisation 'Kidzpositive' at the Groote Schuur Hospital in Cape Town 
provided vital insight into paediatric ARV treatment (Abdullah, 2005). In addition PAWC 
supported other research projects, which also provided useful information on ARVs. PAWC 
has since 2003 had a strong partnership with 'Absolute Return for Kids' (ARK), a non-
governmental organisation. ARK helped with the upscale of new ARV sites, by bringing in a 
team of doctors, nurses and/or pharmacists to rapidly improve capacity at the site (Cloete, 
2005, personal comm., 30 Aug). This happened at many of the ARV sites, however not at the 
five sites funded by the Global Fund. 
The pilot projects in 2000 represented the starting point of providing antiretroviral treatment 
in Western Cape. The later general rollout, in 2004 started with the pilot sites then 
gradually expanding to other sites 10. The 4 Global Fund sites, which were previous pilot 
sites, expanded and upscaled the ARV treatment. The fifth site, the Masiphumelele site in 
Fish Hoek, Cape Town, was set up in late 2004 with the knowledge gained in from the pilot 
project in Gugulethu (Wood, 2005, personal comm., 9 Sept). 
For the Western Cape, partnerships have been an essential component in the fight against 
AIDS. By creating partnerships the province was able to expand their projects and gain 
more knowledge than they would have done without the partnerships. The early experience 
in providing antiretroviral treatment in poor communities in Khayelitsha and Gugulethu 
gave the Western Cape an advantage over other provinces. This was, according to Dr. 
Fareed Abdullah11, the main reasons for the quick upscale and early success (Abdullah, 
2005, personal comm., 19 July). 
Involvement of civil society 
10 A full list of ARV sites pro July 2005 is attached as an annex. 











The provincial administration in the Western Cape had a strong partnership with civil 
society (Cloete, 2005, personal comm., 30 Aug). The province has important partnerships 
with non-governmental and international organisations, like MSF and the Desmond Tutu 
Foundation. In addition the Western Cape had a strong relationship with the activist 
organisation the Treatment Action Campaign (T AC), with ARV counselling in the Western 
Cape being out sourced to NGOs like TAC. The Treatment Action Campaign promoted patient 
advocacy, which insured a strong community involvement mainly through their involvement 
at most of the urban ARV sites. This is evident in Khayelitsha were HIV services were devel-
oped alongside strong civil society pressure and community-based education programmes. 
"1 mean the main success factor is the involvement of TAC, we came with a technique - a 
technical proposal, its possible to treat H1V ... So TAC has been very useful here, in by the 
way; TAC and MSF developed together here in Khayelitsha. When we arrived they were at an 
office in town, they were a few, a few people that formed the community-based community 
rooted TAC - they come from all sorts of places, some they decide to disclose and that's 
something useful for the treatment of the people so that is an enormous factor" (Goemaere, 
2005, personal comm., 5 Aug) 
The Treatment Action Campaign acted on a provincial and national level, mobilising the 
community, making HIV / AIDS and access to ARV s as a political issue. 12 T AC has 
educated many people in the community about HIV / AIDS, prevention and AR V therapy 
("treatment literacy"). In Khayelitsha, TAC's Project Ulwazi ("knowledge") used HIV 
positive people to educate the community, with the goal of promoting disclosure and 
reducing stigma (MSF et ai, 2003). 
"The Treatment Action Campaign brings with it a completely different dimension in terms of 
their partnership. It was more a partnership of encouraging people on the ground to engage in 
the treatment program and doing a lot of mobilisation in communities where the treatment is 
needed, and doing a lot of treatment literacy and a lot of things that kind of combat stigma with 
an exceptional groundwork in terms of making the Western Cape a fertile ground for a good 
roll out program. So that it's dealt with a lot of programs that we would never be able to cope 
with or begin to deal with if we had to do it in absence of that partnership. " (Cloete, 2005, 
personal comm., 30 Aug) 
Although difficult to prove, T AC' s involvement in Khayelitsha, in combination with MSF and 
12 TAG has been on the forefront demanding access to treatment. They have, among other things, taken 
the health minister to court for not allowing HIV positive women to be treated with ARVs so that the 











the provincial administration in the Western Cape might have created more openness and 
knowledge around HIV and AIDS, and possibly reduced stigma. More people in Khayelitsha 
were coming forward for HIV tests and wishing to know their status than in any other 
community, with 60% of women aged 20-24 years had taken an HIV test (Eric Goemaere 
quoted in Rosenberg, 2005). In South Africa, generally, it is believed that the vast majority of 
the people do not know their HIV status. No other community in South Africa can show such 
high results as Khayelitsha (Eric Goemaere quoted in. Rosenberg, 2005). This indicates that 
there is might be more openness around HIV / AIDS in Khayelitsha than in many other areas. 
'Ok. TAC. .. you know that's a good one. I think in Khayelitsha they've been particularly good, 
hey ... and I mean just overall they're good. But in Khayelitsha they've been particularly good. 
And how I think they've helped amazed me. You see I don't think we've had to use ... where in a 
sense nationally TAC has had to be in a sense on the attack to try and force government to do 
things. Here in the Western Cape, TAC and Fareed are particularly very close you know ... and 
they've been able to affirm what we've been doing rather than attack it, and I think that's a 
better relationship and so they've been able to put their energies into helping people 
understand the treatment, understand what the drugs are, understand sort of the potential fall-
outs and things like that why they shouldn't ... So I mean a young client in Khayelitsha on 
antiretrovirals probably knows more about the drugs and the side effects and all that than I do, 
just about ... I mean they're amazingly informed. ' (Toms, 2005, personal comm., 23 Aug) 
In addition to TAC, many other organisations have been active in the fight against HIV/AIDS. 
Academic institutions and researchers have also been involved in discussions on ARV 
treatment (Maartens, 2005, personal comm., 4 Aug). The combination of all these initiatives 
has helped to create a united environment in Western Cape promoting openness around 
HIV/AIDS. 
Synergy 
The united environment around HIV / AIDS in Western Cape created by the involvement of civil 
society created openness and unity. The pilot projects and the partnerships made people think 
that there was a will to do something in the Western Cape. The provincial HIV/AIDS 
administration in the Western Cape was seen as credible; they were doing all they could, in 
light of the national policies, to initiate ARV treatment. All actors in the fight against AIDS 
were in agreement. There were no disparities and controversies like at the national level. In 
the Western Cape all parties wanted to fight AIDS. The government, local authorities, NGOs, 
international donors and clinicians, All were working together to do their best under the 











Western Cape stand out at the forefront in the fight against AIDS. The province was seen as 
innovative, responsive and all-inclusive, attributes which helped it to attracted staff and better 
resources to the Western Cape. Greater trust from civil society and the public led to less 
criticism. 
There was also a strong connection and between the three leading institutions/organisations via 
the three leading men; Fareed Abdullah (PAWC), Zackie Achmat (TAC) and Eric Goemaere 
(MSF), in the fight against AIDS. This naturally eased tension, and helped create synergy. 
"Here in the Western Cape, TAC and Fareed (Abdullah) are particularly very close ... " 
(Toms, 2005, personal comm., 23 Aug) 
Dr Eric Goemaere on his relations with Dr Fareed Abdullah: 
'Excellent - from the beginning; very fruitful. J mean I've been doing this work for MSF for 
more than 30 years and it's definitely the best relation I have ever had. With national it is 
probably the worst J have had. ' (Goemeare, 2005, personal comm., 5 Aug) 
'J think the word for me would be "synergy", particularly with Khayelitsha. TAC, province, 
city... um, youth centres, NGO's involved, MSF, you know ... you've got this synergy going, 
they really and they work together, they think together, they understand each other, they're a 
team' (Toms, 2005, personal comm., 23 Aug) 
Leadership/Management 
The decision to involve civil society and establish partnerships was taken by the HIV/AIDS 
management team, led by Deputy Director Dr Fareed Abdullah. In this research the 
management style of the HIV/AIDS team in Western Cape has come out as an important 
factor in the success of the Global Fund grant. Almost all interviewed, in the research 
process, acknowledged the importance of Dr Fareed Abdullah's leadership and his team's 
well functioning management style. Several visualised how well the Western Cape 
functioned in comparison to the neighbouring province of the Eastern Cape, where things 
run much less smoothly. One interviewee went as far as saying that working in the Eastern 
Cape was impossible without a drastic change in management. However since the focus of 
this dissertation is not on the Eastern Cape, this section will explore what made the ARV 











For any programme to be successful you need good management and well functioning systems 
in place. This is particularly important in the context of the Global Fund. The Global Fund 
requires progress reports and the Local Fund Agent assesses the grant performance, making 
monitoring and evaluation a crucial part of grant management. If a grant is not performing well, 
and not reaching its targets, or if it is not accountable, then the grant faces the risk of 
termination. This has recently been seen with the Global Fund grant to love Life in South 
Africa. LoveLife applied for 'phase two' funding, however the application was declined. This 
resulted in 10veLife loosing one third of its funding, which naturally has adverse implications 
on their project. The grant given to Western Cape will also face termination if it does not 
continue performing well, thus good management to meet targets will be vital. 
In the Western Cape, Dr. Fareed Abdullah was in charge of the HIV/AIDS team, which is also 
the unit that is responsible for the Global Fund grant (Global Fund, 2006). The implementation 
and management of the Global Fund grant had been carried out within existing programmes in 
the provincial administration in Western Cape (Frankish, 2005, personal comm., 22 July), and 
parallel systems and structures, apart from the special ARV depot, have not been developed 
(Abdullah, 2005, personal comm., 19 July). Even though the existing management personnel, 
structures and systems have managed and implement the Global Fund grant, only a handful 
additional personnel were appointed in the first year of the grant to coordinate the Global Fund 
aspects of the already existing programmes (Frankish, 2005, personal comm., 22 July). 
One dedicated manager, Dr. John Frankish acts as the Global Fund Manager in Western Cape 
and the HIV/AIDS management team also deals with the daily managing of the Global Fund 
grant (Frankish, 2005, personal comm., 22 July). A few other key personnel have been hired to 
make sure the team produces regular operational, monitoring and financial reports as required 
by the Global Fund, and makes sure the grant performs well (Frankish, 2005, personal comm., 
22 July) They can be summed up as: 
• One Provincial Global Fund Programme Manager 
• One Provincial Global Fund Financial Administrator 
• Four Regional Global Fund Financial Administrators 
• One Regional Global Fund Peer Education Administrator 











the progress of the grant (Abdullah, 2005, personal comm., 19 July). These meetings created 
peer pressure with regards to performance, making the responsibilities more focused on 
meeting targets (Naidoo, 2005, personal comm., 1 Aug). Thus this management and 
infra structural supporting frameworks can be attributable to the successful management and 
meeting of targets for the Grants. 
Jt's almost the perfect example. J've never seen such a good example of funding that 
instead of making people dependent. stimulate their ambition" (Goemaere, 2005, personal 
comm., 5 Aug) 
The members of the antiretroviral management team who were interviewed for this dissertation 
all highlighted the good team spirit and that the team was very strong; 
"J think we've got a very good team spirit ... dealing with the Global Fund was actually quite 
a good team-building exercise" (Cloete, 2005, personal comm., 30 Aug) 
Dr Fareed Abdullah has been responsible for the Western Cape's AIDS programme since 1995 
(Herman, 2006). In 1999 he had the courage and dedication to start the first HIV prevention 
programme of mother to child transmission in South Africa (Goemaere, 2005, personal comm., 
5 Aug). Abdullah also had the foresight to sign an agreement with MSF to do pilot research on 
ARVs (Goemaere, 2005, personal comm., 5 Aug). 
'It was a political risk ... ' The management style was fantastic' (Maartens, 2005, personal 
comm., 4 Aug) 
There were these huge tensions with the national minister and she was saying that AZT was 
poison ... ' (Toms, 2005, personal comm., 23 Aug) 
It takes a strong leadership to go against national policies; it takes a visionary to unite the 
province. It takes charisma and motivation to attract good a good management team. These are 
all qualities about Dr Fareed Abdullah that have come up in interviews. Many have attributed 
the success of AIDS treatment in the Western Cape to a large extent to Dr Abdullah's drive and 
commitment. 
'/ think a huge amount of that must go to Fareed's (Abdullah) drive and commitment ... That J 
fully take my hat off for what he's done in terms of that and be able to put together that Global 












'Fareed (Abdullah) is also a very strong leader and a good visionary. He always challenges 
you, but supports you to the goa!. .. hke he he'll say "We are going to do this ... " and we'll all 
look at each other and think oh how are we going to do this? I don't know if it is his charisma 
or what it is, but somehow he inspires us to get there and he supports us through the process as 
well which has been great. I think he is also one of our KEY success factors. ' (Channing, 
2005, personal comm., 25 Aug) 
Dr Abdullah also had the vision to apply for funding from the Global Fund despite the 
controversies in KwaZulu-Natai. When MSF's Dr Eric Goemaere was asked "could it have 
been done without him?" he replied: 
''I'm not sure. It's a good question, and relevant question. I'm not sure ... his skills, his style; 
he is very good in creating a team. He managed to create a management team - Have you see 
a management team like that at national level? It is a big job and he has charisma, vision, he 
sees far, and that makes a big difference I think. " (Goemaere, 2005, personal comm., 5 Aug) 
All through the research the role that Dr Fareed Abdullah's played in the management of the 
grants was mentioned repeatedly, and he has been described as the driving force for the ARV 
success in Western Cape. He was said to be a good visionary leader, who motivated his staff. 
Many highlighted his ability to put together a strong ARV management team. 
'I think that Fareed is quite lucky and fus!;y in terms of the fact that he tends to chose hand 
picked people that he involves in his team ... He is clearly a very committed person ... He is very 
honest and re!;pects whatever you say ... He chooses people who are highly motivated, who can 
get the job done, and who have done well and shown that they can do well in difficult 
circumstances. Those are the people that he has pulled into the team '. (Stingers, 2005, personal 
comm., 1 Sept) 
'I think one of the things that Fareed did, in his wisdom did bring a pharmacist into 
programme, which never happened before. So very often I would sit in meetings and they will 
be planning things, planning changes and obviously a pharmacist could see things from 
different perspectives ... A clinician would say 'we need this treatment' a pharmacist might say 
'look we have this stock, it's worth this amount of money and we need to get rid of it before we 
can ... ' so we just see things differently. So I think it was very good that Fareed brought a 
pharmacist into programs in general and then specifically into the ARV. I form part of a core 
team so we have somebody looking after clinical, somebody looking after the site ... I look after 
medicines and pharmacy related issues and I think that helped a lot as well.' (Channing, 2005, 
personal comm., 25 Aug) 











Dr Fareed Abdullah was especially given credit for hiring Dr John Frankish (Boulle, 2005, 
personal comm., 10 Aug). 
'We are very lucky to have John (Frankish) , (Slingers, 2005, personal comm., 1 Sept) 
'John Frankish is no 'nobody' you know, these guys manage huge budgets, they know about 
management, and of course there's the whole capacity. I hear in another country is too 
complicated the Global Fund, and here its works perfectly. Again, on both sides there were 
good political reason to make sure it worked and rapidly. But it was sort of a dream story 
because of the relations with the Global Fund, we were helping each other in the best way to 
create out of it the best outcome we could have, and the Global Fund has stimulated their 
energy, their enthusiasm and their ambition. " (Goemaere, 2005, personal comm., 5 Aug) 
It was a calculated management decision to select the five chosen Global Fund ARV sites 
(Abdullah, 2005, personal comm., 20 July). Starting up new ones would have demanded more 
work and would have been riskier (Naidoo, 2005, personal comm., 1 Aug). It was also 
calculated to keep the number of ARV sites in Western Cape to a low number around 40 
(Cloete, 2005, personal comm., 30 Aug). As by limiting the number of clinics it was easier to 
manage the ARV supply, and to ensure that they were adequately staffed (Cloete, 2005, 
personal comm., 30 Aug). By following this strategy the Western Cape made sure that they 
reached their Global Fund targets and reached as many people in the shortest time with ARVs 
(Cloete, 2005, personal comm., 30 Aug). 
"As I say it's almost the perfect example. I've never seen such a good example of funding that 
instead of making people dependent stimulate their ambition, I mean, they could have ... they 
could have sit on the global fund money and stick to that but they say ok, we can get that bit 
and save a bit of money and do it elsewhere. So I know that they could have asked national 
well, why it works so much. No, no, they really pushed the roll- out - the provincial roll out as 
far as they could, save in ~ from the global fund to invest else where. " (Goemaere, 2005, 
personal comm., 5 Aug) 
Limiting the number of province run ARV sites was a bold strategy, which has received a lot of 
criticism for being a short-term solution (Goemaere, 2005, personal comm., 5 Aug; Toms, 
2005, personal comm., 23 Aug). The ARV treatment is managed by the province, it has its own 
medical depot, and it is provided in selected clinics only. The programme has not been 
integrated into the primary health care setting, as have the treatments for opportunistic diseases 
such as Tuberculosis have been. This could be problematic in the long run, but was described 
as a short-term necessity for the Western Cape (Cloete, 2005, personal comm., 30 Aug). This 











treatment as fast as possible (Abdullah, 2005, personal comm., 23 Sept). And when people 
where dying of AIDS, it was important to save as many as possible as quickly as possible. 
However, the understanding is that after some years the ARV programme will be incorporated 
into the primary health care system, ensuring even broader access (Abdullah, 2005, personal 











CHAPTER 7: Challenges 
Key success factors such as partnership, experience, timing, management and synergy have all 
contributed to the success of the Global Fund grant in Western Cape. Even though the Western 
Cape and the Global Fund grant are seen as successful by many of the people interviewed for 
this dissertation, several challenges still remain. 
Firstly, the numbers of people who need ARVs is increasing, and will keep increasing for the 
foreseeable future, and if nothing changes this poses challenges in infrastructure and staffing. 
PAWC has gone for a wide spread ARV rollout model with 44 sites. This model is not 
designed to incorporate all the HIV positive people who are or will be in need of ARVs for the 
next 10 to 20 years. Clinics which operated on maximum capacity in 2005 will naturally need 
to expand capacity to be able to operate in 2006 and 2007. If this means that there will be needs 
such as an extra building and additional staff, these are challenges that have to be met by 
PAWC. Often building an extra facility takes a number of years with a slow moving 
bureaucracy like the Western Cape (Cloete, 2005, personal comm., 30 Aug). This was evident 
when the Gugulethu ARV site needed a new building to be able to scale up the provision of 
ARVs in 2004 (Slingers, 2005, personal comm., 1 Sept). This building was completed in 2005, 
resulting in the uptake of patients rising dramatically. This new building was according to 
Slingers, 2005 (personal comm., 1 Sept) the reason for the Gugulethu site meeting its Global 
Fund targets. 
The MSF in Khayelitsha did not possess that kind of patience and set up an extra building 
themselves (Slingers, 2005, personal comm., 1 Sept). This is well and good for the patients who 
need ARVs in Khayelitsha, but it highlights a potential huge challenge for PAWC's ARV 
management team. In the longer term, what will happen when the 44 sites reach absolute 
maximum capacity? The PAWC has chosen a rather vertical approach to ARV delivery. The 
drugs are supplied by a special ARV depot, and given at special ARV clinics. This vertical 
approach will need to be generated into the primary health care to insure best possible access, 
both in terms of people needing treatment and geographical access. Studies have clearly shown 
that vertical policies often are favoured for a quick and easy outreach, never the less; fail to 
achieve the same level of success in the long run. The best possible solution for ARV delivery 











service. This will be a huge challenge for PA WC to integrate HIV/AIDS with other diseases 
like TB at a primary health care facility. ARV drugs should also be integrated in the general 
depot, and that can pose big challenges for the province. Quick fix solutions might be essential 
in reaching big numbers but to achieve universal access to ARV treatment, one needs to focus 
on long term issues. People are still getting infected by HIV, and the number of patients 
needing treatment will only increase as long as new people are infected and the ones who are 
on treatment live longer. 
Secondly, medical staff, especially nurses are hard to find (Frankish, 2005, personal comm., 26 
Aug). Cape Town has been fortunate to attract medical staff to its urban clinics (Slingers, 2005, 
personal comm., 1 Sept). If medical staff is taken from other health services, this might create a 
backlash were other essential medical areas lack staff as ART jobs are more attractive with 
higher salaries. Workloads in ARV clinics might lead to increased stress as clinics reach 
maximum capacity due to high uptakes of ARV patients, which might cause medical staff to 
seek other less stressful jobs. This is particularly challenging for the more rural clinics. The 
Western Cape is fortunate to have and has great need for their partnership with ARK, which 
helps recruit staff. Without the continuing support from NGOs, once again, PAWC seems more 
fragile. 
Thirdly, the province has relied on external funding from the Global Fund to finance a large 
share of the antiretroviral treatment rollout. As of current rules, the Global Fund only finances 
grants for a 5 year period. Since the fund is relativly new, no grants have reached this 5 year 
mark, and policies for continued funding have not yet been decided. In 2009, when the Western 
Cape Global Fund grant is at is 5 year mark, funding from the Global Fund will stop. As 
discussed above, the numbers of people needing treatment will keep increasing, so the need for 
more money to finance this upscale is essential. This funding will have to be secured through 
national funds if no more external funds become available, meaning that the Western Cape will 
then have to compete with other provinces to get sufficient funding. 
Fourthly, as the Western Cape was the first government programme to put people on ARVs, it 
is likely that the province will experience an in creasing number of patients which develop drug 
resistance and/or need to change the drug combination due to complications, thus the need for 
the more expensive second line ARVs will keep increasing. This makes the financial 











more expenSIve second line ARV s, this will pose Immense financial challenges for the 
prOVInce. 
The fifth challenge is the role of nutrition in successful ARV treatment. Key personnel in 
PA WC have mentioned, in interviews, that they underestimated the importance of nutrition, 
and should have included nutrition in the Global Fund application (Frankish, 2005, personal 
comm., 26 Aug). Lack of proper nutrition effects the ARV treatment, and in poor areas like 
Khayelitsha PA WC could have provided food parcels to patients on ARVs. Naturally this is a 
logistical and financial challenge which needs to be highlighted. 
As seen in the chaIlenges mentioned above, PA WC faces a number of serious chaIlenges for a 
successful long term integrated programme. Slingers (2005, personal comm., 1 Sept) 
commented that much of the Western Cape ARV management team's success up to date can be 
attributed to a focused team with a 'can do' spirit. She recaIled how they approached challenges 
and worked hard to solve problems and challenges. For example, how they phoned up doctors 
and nurses and personaIly asked them to come and work at an ARV site. Cloete further 
reiterated how a management team handles problems and challenges can say a lot about how 
weIl functioning the management is. 
'One oj the key success Jactors Jor me is the manner in which we manage challenges' (Cloete, 
2005, personal comm., 30 Aug) 
As the previous chapter has mentioned, the management of the Global Fund grant in Western 
Cape has been hailed as one of the success factors. Much credit has been given to the leader, Dr 
Fareed Abdullah and his strong management team. As of January 13 2006 Dr AbduIlah has 
resigned from his position (Keeton, 2006), leaving it to his team to foIlow up his successful 













Access to the life saving antiretroviral treatment has caused much controversy in South Africa, 
with more than 5.2 million South Africans affected with HlV/AIDS. South Africa ranks as the 
country with the highest number of people infected, and AIDS is the country's number one 
killer. Thus the arrival of antiretroviral treatment (ART) has given hope to millions of people 
living with HIV/AIDS. 
This dissertation has shown that the Provincial Department of Health in Western Cape was one 
of the first to start providing ART in South Africa. In 2003 the department applied for external 
funding from the Global Fund to fight AIDS, Tuberculosis and Malaria. Having presented a 
successful proposal, the Western Cape was able to rapidly scale up their AIDS treatment 
though out the province by employing more people on the ART campaign. Through this 
campaign more than 11 000 people living with HIV/AIDS are now receiving ART with 2750 
being funded by the Global Fund money. This success has resulted in the Western Cape rollout 
being refereed to by experts as the ARV success story of the country. 
This dissertation has shown how the Global Fund grant has, in it first year, clearly meet and 
in some cases exceeded its targets on ARV treatment. The following key factors have been 
presented that have contributed to this success: 
1. The Western Cape had an advantage over other provinces as a result of their 
progressive and committed management team. 
2. Having already initiated the provision of antiretroviral drugs back in 1999 in order to 
prevent HIV positive women of transmitting the infection to their infants and coupled 
with the experience gained from the three years of ARVs pilot projects in 
Khayelitsha and in Gugulethu, this has enabled them to more easily expand the 
rollout to the rest of the Western Cape. This was assisted by the successful 
application of the Global Fund grant and national funds, which enable them to 
provide ARV treatment, thus creating the basis for a successful programme 
Based on these factors and achievement in meeting targets and objectives it is considered a 











spent. There is further evidence to support these finding and these can be seen by historic view 
of ARV treatment in Western Cape provided within the dissertation. 
The Western Cape Provincial Government has shown the rest of South Africa, that providing 
antiretroviral treatment through the public health service is possible, both in rural areas and 
urban poor areas like Khayelitsha. Through the research process it has been identified that the 
Western Cape Global Fund grant in the first year of the grant is a successful grant. Other 
provinces could learn and benefit from the experience and approaches the Western Cape has 
taken. They too could apply for external funding for ARV provision to build a stronger 
treatment programme. 
Based on the research it is the perception of most interviewed that the Western Cape Province 
has the best possible outlook for the grant in years to come. It will be interesting to monitor 
the success of the second year of the grant now that the Western Cape Provincial HIV / AIDS 
key leader, Dr Fareed Abdullah has resigned as of 13 January 2006. This will be of particular 
interest since the research has hailed Dr Abdullah as one of the key factors for the success of 
the grant. The true test will be to see if the remaining management team and new leader will 
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Appendix: A - List of ARV sites in the Western Cape per July 2005 
ARV sites in Western Cape pr. July 2005; the highlighted ones are supported by money from 
the Global Fund to fight AIDS, Tuberculosis and Malaria. 
1. Groote Schuur Hospital 2. Tableview 
3. Red Cross Hospital 4. Cloetesville DH 
5. Tygerberg Hospital 6. Swartland 
7. G.F. Jooste Hospital 8. TC Newman Hospital 
9. Hottentots Holland Hospital 10. Vredenberg 
11. Victoria Hospital 12. Vredendahl 
13. Guguletu CHC 14. Citrusdahl 
15. Masiphumelele Clinic 16. Ceres Hospital 
17. Michael M CHC 18. Eben Donges Hospital 
19. Nolungile CHC 20. Grabouw 
21. Site B, Khayelitsha CHC 22. Hermanus 
23. Crossroads 24. Robertson 
25. Eersterivier 26. Swellendam 
27. Kraaifontein 28. Beaufort West Hospital 
29. Mitchells Plain CHC 30. George Hospital 
31. Robbie Nurrock 32. Knysna 
33. Westfleur Hospital 34. Mosselbaai 
35. Hout Bay Clinic 36. Oudtshoorn 











Appendix: B - Interviews and personal communication 
Person Date 
Fareed Abdullah 19 July 2005 
20 July 2005 
23 Sept 2005 
Andrew Boulle 10 August 2005 
Liezl Channing 25 August 2005 
Keith Cloete 30 August 2005 
John Frankish 22 July 2005 
26 August 2005 
Eric Goemaere 5 August 2005 
Gray Maartens 4 August 2005 
Pren Naidoo 1 August 2005 
Nevilene Slingers 1 September 2005 
Ivan Toms 23 August 2005 











Appendix: C - Global Fund to fight AIDS, Tuberculosis and Malaria -
Board members* 
*As per 28.January 2006 according to the Global Fund's website 
http://www . theg lobalfund .org/en/about/board/members/ 
Voting Board Members 
Canada (Germany & Switzerland) 
Dr. Ernest Loevinsohn 
Director General 
Program Against Hunger, Malnutrition and Disease 
Canadian International Development Agency 
Canada 
Communities (NGOs representative ofthe Communities Living with the Diseases) 
Ms. Anandi Yuvaraj 
Program officer of India HIV/AIDS Alliance 
India 
Developed Country NGO 
Mr. Peter van Rooijen 
Stop AIDS Now! 
The Netherlands 
Developing Country NGO 




Eastern Europe (Romania) 
Mr. Eugen Nicolaescu 
Minister of Health 
Romania 
Eastern Mediterranean Region 
Mr. Abdullah Abdillahi Miguil 
Minister of Health 
Djibouti 
Eastern and Southern Africa (Angola) 
Dr. Jose Viera Dias Van D?/a> 
Deputy Minister of Health 
Angola 
European Commission (Austria, Belgium) 
Dr. Lieve Fransen 
Head of Unit 
Human and Social Development 
European Commission 
Belgium 
France (Luxemburg, Spain) 
Prof. Serge Tomasi 













Mr. Giuseppe Deodato 
Director-General Development Cooperation 
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Appendix: D - List of ARVs stocked in the ARV depot as per April 
2005. 
DESCRIPTION TRADE NAME STRENGTH COMPANY QTY 
ZERIT CAPS 20mg BMS 56 
30mg BMS 56 
Stavudine 40mg BMS 56 
(D4T) ZERIT SOLN 1mg/ml BMS 200ml 
ZIAGEN TABS 300mg GSK 60 
Abacavir ZIAGEN SOLN 20mg/ml GSK 240ml 
25mg ASPEN 60 
50mg ASPEN 60 
Didanosine 100mg ASPEN 60 
(001) 150mg ASPEN 60 
Zidovudine ASPEN ZIDOVUDINE 10MG/ML ASPEN 200ML 
(AZT) ASPEN ZIDOVUDINE 300MG ASPEN 60 
(NVP) ASPEN NEVIRAPINE 200MG ASPEN 60 
AZT/3TC LAMZID 300/150mg ASPEN 60 
NORVIR CAPS 100mg Abbott 84 
Ritonavir NORVIR SYRUP 80mg/ml Abbott gOml 
ZERIT CAPS 20mg BMS 56 
30mg BMS 56 
Stavudine 40mg BMS 56 
(D4T) ZERIT SOLN 1mg/ml BMS 200ml 
ASPEN STAVUDINE 20mg ASPEN 60 
Stavudine ASPEN STAVUDINE 30mg ASPEN 60 
(D4T) ASPEN STAVUDINE 40mg ASPEN 60 
Stavudine STAVIR 30mg CIPLA 60 
(D4T) STAVIR 40mg CIPLA 60 
RETROVIR CAPS 100mg GSK 100 
RETROVIR TABS 250mg GSK 60 
RETROVIR CAPS 300mg GSK 60 
Zidovudine RETROVIR IV GSK 20 ml (5) 
(AZT) RETROVIR SYR 10mg/ml GSK 200 ml 
Zidovudine ASPEN ZIDOVUDINE 10MG/ML ASPEN 200ML 











DESCRIPTION TRADE NAME STRENGTH COMPANY Qty 
Lamivudine 3TC TABS 150mg GSK 60 
(3TC) 3TC SYRUP 10mg/ml GSK 240 ml 
ASPEN STAVUDINE 20mg ASPEN 60 
Stavudine ASPEN STAVUDINE 30mg ASPEN 60 
(D4T) ASPEN STAVUDINE 40mg ASPEN 60 
AZT/3TC COMBIVIR TABS 300/150mg GSK 60 
r 
KALETRA CAPS 133/33 Abbott ritonavir 2x90 
(LPV/r) KALETRA SYR 80/20 Abbott 5x60ml 
NORVIR CAPS 100mg Abbott 84 
Ritonavir NORVIR SYRUP 80mg/ml Abbott 90ml 
RETROVIR CAPS 100mg GSK 100 
RETROVIR TABS 250mg GSK 60 
RETROVIR CAPS 300mg GSK 60 
Zidovudine RETROVIR IV GSK 20 ml (5) 
(AZT) RETROVIR SYR 10mg/ml GSK 200 ml 
Stavudine STAVIR 30mg CIPLA 60 
(D4T) STAVIR 40mg CIPLA 60 
STOCRIN CAPS 50mg MSD 30 
STOCRIN CAPS 200mg MSD 90 
Efavirenz STOCRIN TABS 600MG MSD 30 
Nevirapine VIRAMUNE TABS 200mg B Ingelheim 60 
(NVP) VIRAMUNE SYR 10mg/ml B Ingelheim 240ml 
VIDEX TABS 25mg BMS 60 
VIDEX TABS 50mg BMS 60 
VIDEX TABS 100mg BMS 60 
Didanosine VIDEX TABS 150mg BMS 60 
(001) VIDEXPWD 2g BMS 1 
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